A Multicenter Open-label Extension Study to Assess the Safety and Tolerability of LYC-30937-EC in Subjects With Active Ulcerative Colitis
Phase: PHASE2
Conditions: Colitis, Ulcerative
Sponsor: Lycera Corp.



 
Clinical Protocol 
LYC-30937-2002 
Amendment 2, 22 November 2016 
 
Confidential and Proprietary 
Page 2 of 56 
TABLE OF CONTENTS 
TABLE OF CONTENTS ..............................................................................................................2 
LIST OF TABLES .........................................................................................................................4 
LIST OF ABBREVIATIONS .......................................................................................................5 
1.0 
PROTOCOL SUMMARY ................................................................................................8 
2.0 
INTRODUCTION............................................................................................................11 
2.1 
Background ............................................................................................................11 
2.2 
Rationale for the Study ..........................................................................................12 
2.3 
Nonclinical Studies ................................................................................................13 
2.3.1 
Nonclinical Pharmacology .............................................................13 
2.3.2 
Nonclinical Pharmacokinetics .......................................................14 
2.3.3 
Safety Pharmacology and Toxicology ...........................................14 
2.4 
Previous Human Experience ..................................................................................15 
2.5 
Dose Selection Rationale .......................................................................................16 
2.6 
Risks and Benefits..................................................................................................17 
3.0 
STUDY OBJECTIVES AND ENDPOINTS ..................................................................18 
3.1 
Study Objectives ....................................................................................................18 
3.1.1 
Primary Study Objective ................................................................18 
3.1.2 
Exploratory Objective ....................................................................18 
3.2 
Endpoints ...............................................................................................................18 
3.2.1 
Safety Endpoint:.............................................................................18 
3.2.2 
Exploratory Endpoint: ....................................................................18 
4.0 
STUDY DESIGN ..............................................................................................................19 
4.1 
Design Overview ...................................................................................................19 
4.2 
Number of Subjects and Sites ................................................................................19 
4.3 
Assignment of Subject Numbers ...........................................................................19 
4.4 
Subject Selection ....................................................................................................20 
4.4.1 
Inclusion Criteria ...........................................................................20 
4.4.2 
Exclusion Criteria ..........................................................................20 
4.5 
Subject Withdrawals ..............................................................................................21 
5.0 
STUDY TREATMENTS .................................................................................................22 
5.1 
Description .............................................................................................................22 

 
Clinical Protocol 
LYC-30937-2002 
Amendment 2, 22 November 2016 
 
Confidential and Proprietary 
Page 3 of 56 
5.2 
Treatment Regimen ................................................................................................22 
5.3 
Drug Supplies.........................................................................................................22 
5.3.1 
Packaging and Labeling .................................................................22 
5.3.2 
Product Accountability, Storage, Dispensing and Return .............23 
5.3.3 
Treatment Compliance ...................................................................23 
5.4 
Concomitant Medications ......................................................................................24 
6.0 
STUDY PROCEDURES .................................................................................................24 
6.1 
Visit Timing ...........................................................................................................24 
6.2 
Schedule of Events .................................................................................................26 
6.2.1 
Eligibility Visit 1............................................................................29 
6.2.2 
Visits 2, 3, 4, 5, 6, 7 (Weeks 2, 4, 6, 8, 20, 32) ..............................31 
6.2.3 
Visit 8 or Early Termination (Week 44) ........................................32 
6.2.4 
Visit 9 Follow-Up (Week 46) ........................................................32 
6.2.5 
Unplanned Visits ............................................................................32 
6.3 
Subject Diary .........................................................................................................33 
6.4 
Safety Assessments Performed ..............................................................................33 
6.4.1 
Physical Examinations ...................................................................33 
6.4.2 
Vital Signs Measurements .............................................................33 
6.4.3 
12-Lead Electrocardiogram ...........................................................34 
6.4.4 
Laboratory Assessments ................................................................34 
6.4.5 
Body Temperature Monitoring ......................................................35 
6.4.6 
Monitoring Subjects for Adverse Events of Special Interest .........36 
7.0 
ADVERSE EVENTS AND SAFETY MONITORING ................................................38 
7.1 
Adverse Event Definition ......................................................................................38 
7.2 
Serious Adverse Events Definition ........................................................................39 
7.3 
Adverse Event Reporting .......................................................................................39 
7.4 
Assessment of Severity of Adverse Events ...........................................................40 
7.5 
Serious Adverse Event Reporting ..........................................................................41 
7.6 
Post-Week 46 Reporting of Serious Adverse Events ............................................43 
7.7 
Exposure in Utero (EIU) ........................................................................................43 
7.8 
Relationship/Causality of Adverse Events/Serious Adverse Events .....................44 
7.9 
Withdrawal Due to Adverse Events .......................................................................44 

 
Clinical Protocol 
LYC-30937-2002 
Amendment 2, 22 November 2016 
 
Confidential and Proprietary 
Page 4 of 56 
7.10 
Medical Monitoring ...............................................................................................45 
7.11 
Stopping Rules .......................................................................................................45 
7.11.1 
Suspension of Study .......................................................................45 
8.0 
STATISTICAL AND ANALYTICAL PLAN ...............................................................46 
8.1 
Analysis Populations ..............................................................................................46 
8.1.1 
Safety Set .......................................................................................46 
8.2 
General Statistical Considerations .........................................................................46 
8.3 
Demographic and Subject Characteristics .............................................................46 
8.4 
Safety Analysis ......................................................................................................46 
8.5 
Exploratory Efficacy Analysis ...............................................................................47 
9.0 
ETHICAL CONSIDERATIONS ....................................................................................47 
9.1 
Basic Principles ......................................................................................................47 
9.2 
Institutional Review Board / Independent Ethics Committee................................47 
9.3 
Informed Consent...................................................................................................47 
9.4 
Study Termination .................................................................................................47 
10.0 
DATA HANDLING AND RECORD KEEPING ..........................................................48 
10.1 
Study Monitoring ...................................................................................................48 
10.2 
Study Documentation.............................................................................................48 
10.3 
Record Retention ...................................................................................................49 
11.0 
CONFIDENTIALITY AND PUBLICATION PLAN...................................................50 
11.1 
Confidentiality .......................................................................................................50 
11.2 
Publication of Data and Protection of Intellectual Property ..................................50 
12.0 
REFERENCES .................................................................................................................51 
13.0 
APPENDICES ..................................................................................................................53 
13.1 
Appendix A: Total of Blood Volume ....................................................................53 
14.0 
DOCUMENT HISTORY ................................................................................................54 
 
LIST OF TABLES 
Table 1 
Schedule of Events ...........................................................................................26 

 
Clinical Protocol 
LYC-30937-2002 
Amendment 2, 22 November 2016 
 
Confidential and Proprietary 
Page 5 of 56 
LIST OF ABBREVIATIONS 
ADL 
activities of daily living 
AE 
adverse event 
ALP 
alkaline phosphatase 
ALT 
alanine aminotransferase 
ASA 
aminosalicylic acid 
AST 
aspartate aminotransferase 
ATP 
adenosine triphosphate 
ATPase 
mitochondrial ATP synthase enzyme 
AUC 
area under the plasma concentration-time curve 
AUC0-24 
area under the plasma concentration-time curve from time 0 to 24 hours postdose  
BP 
blood pressure 
BUN 
blood urea nitrogen 
CD 
Crohn’s Disease 
CFR 
Code of Federal Regulation 
Cmax 
maximum plasma concentration 
CPK 
creatine phosphokinase 
CRF 
case report form 
CRO 
contract research organization 
CTCAE 
Common Terminology for Adverse Events 
CYP 
Cytochrome P450  
DBP 
diastolic blood pressure 
EC 
enteric coated 
ECG 
Electrocardiogram 
EIU 
exposure in utero  
FDA 
Food and Drug Administration 
FE 
food effect 
GCP 
good clinical practice 
GLP 
good laboratory practice 
HDL 
high density lipoprotein 
HEENT 
head, eyes, ears, nose and throat 
HPMC 
hydroxyl-propyl methyl-cellulose 
HR 
heart rate 
hsCRP 
high sensitivity C-reactive protein 
IB 
Investigator’s brochure 
IBD 
inflammatory bowel disease 
IC50 
50% inhibitory concentration 

 
Clinical Protocol 
LYC-30937-2002 
Amendment 2, 22 November 2016 
 
Confidential and Proprietary 
Page 6 of 56 
ICD 
informed consent document 
ICH 
International Council for Harmonisation 
IEC 
independent ethics committee 
INR 
international normalized ratio 
IP 
investigational product 
IRB 
institutional review board 
IWRS 
interactive web-based response system 
LDH 
lactate dehydrogenase 
LDL 
low density lipoprotein 
MAD 
multiple ascending dose 
MCH 
mean cell hemoglobin 
MCHC 
mean corpuscular hemoglobin concentration 
MCV 
mean corpuscular volume 
NCI 
National Cancer Institute 
NOAEL 
no observed adverse effect level 
OL 
open-label 
OLE 
open-label extension 
OXPHOS 
oxidative phosphorylation 
PE 
physical examination 
PK 
pharmacokinetics 
PT 
prothrombin time 
PVSS 
Pharmacovigilance and Safety Services 
q.d. 
Quaque Die, once daily 
QTcF 
QTc interval corrected for heart rate according to Fredericia’s formula 
RBC 
red blood cell  
ROS 
reactive oxygen species 
RR 
respiration rate 
SAD 
single ascending dose 
SAE 
serious adverse event 
SAP 
statistical analysis plan 
SBP 
systolic blood pressure 
SUSAR 
suspected unexpected serious adverse reaction 
T 
Temperature 
TEAE 
treatment emergent adverse event 
TESAE 
Treatment emergent serious adverse event 
tmax 
time to maximum plasma concentration  
TNBS 
trinitrobenzene sulfonic acid 
UC 
ulcerative colitis 

 
Clinical Protocol 
LYC-30937-2002 
Amendment 2, 22 November 2016 
 
Confidential and Proprietary 
Page 7 of 56 
ULN 
upper limit of normal 
US 
United States 
WBC 
white blood cell 
 

 
Clinical Protocol 
LYC-30937-2002 
Amendment 2, 22 November 2016 
 
Confidential and Proprietary 
Page 8 of 56 
1.0 
PROTOCOL SUMMARY 
Indication 
Ulcerative Colitis (UC) 
Study Rationale 
Inflammatory bowel disease (IBD) is a complex autoimmune disorder that consists of UC, 
Crohn’s Disease (CD), and non-specific colitis that remains a disease of high unmet medical 
need.  Current therapies are limited by either low response rates or poor tolerability.  LYC-30937 
enteric-coated (EC) acts to induce apoptosis of chronically activated lymphocytes such as those 
thought to drive the inflammation of UC.  LYC-30937 demonstrated efficacy in animal models 
of IBD and selective induction of apoptosis in chronically activated human lymphocytes.  
LYC-30937-EC has also shown safety, tolerability, and a favorable pharmacokinetic (PK) profile 
in healthy subjects up to single doses of 300 mg, 7 days of daily dosing at 200 mg, and in UC 
subjects in single doses of 25 and 100 mg.  The mechanism of action of selective induction of 
apoptosis in chronically activated lymphocytes, the demonstration of efficacy in IBD models, 
and the safety, tolerability, and PK profile demonstrated in the Phase 1 program supports the 
further assessment of the efficacy of LYC-30937-EC in inducing remission in subjects with 
active UC. 
Study Objectives 
The objective of this open-label extension study is to allow subjects who complete the 
randomized, double-blind, placebo-controlled Phase 2 study, LYC-30937-2001, the opportunity 
to receive LYC-30937-EC and it will allow collection of additional information on the safety and 
tolerability of LYC-30937-EC in subjects with UC. 
Primary Objectives 
The primary objective will be to assess the safety and tolerability of LYC-30937-EC in subjects 
with UC. 
Exploratory Objective 
An exploratory objective will assess symptoms of UC. 
Study Population 
Eligible subjects for study are those who completed study LYC-30937-2001. 

 
Clinical Protocol 
LYC-30937-2002 
Amendment 2, 22 November 2016 
 
Confidential and Proprietary 
Page 9 of 56 
Treatment and Duration 
All subjects who meet the eligibility criteria will receive treatment with LYC-30937-EC 25 mg 
once daily (q.d.) and taken orally in a fasted state.  The treatment period is up to 44 weeks 
followed by a 2-week safety follow-up period.  
Assessments 
Safety assessments: 
Adverse events (AEs) will be collected from the time of signing the informed consent.  All 
subjects who are randomized will be monitored for AEs until the time they leave the study. 
Additional safety assessments: 
 Vital signs including body temperature 
 Physical examinations (PEs) 
 12-lead Electrocardiograms (ECGs) 
 Clinical laboratory assessments 
 AEs of special interest 
Endpoints  
Safety Endpoint: 
 The incidence and type of AEs, serious AEs (SAEs), and AEs that led to discontinuation of 
treatment, laboratory assessments, vital sign measurements, ECGs, and PEs. 
Anticipated Number of Subjects  
Up to approximately 120 subjects will have the opportunity to receive LYC-30937-EC 25 mg. 
Anticipated Number of Sites 
Up to approximately 66 sites  
First Subject Enrolled 
4th Quarter 2016 

 
Clinical Protocol 
LYC-30937-2002 
Amendment 2, 22 November 2016 
 
Confidential and Proprietary 
Page 10 of 56 
End of Study 
Last subject visit approximately November 2018  
Study Countries 
North America (Canada, United States), Europe (Czech Republic, Hungary, Netherlands, Poland, 
Serbia) 

 
Clinical Protocol 
LYC-30937-2002 
Amendment 2, 22 November 2016 
 
Confidential and Proprietary 
Page 11 of 56 
2.0 
INTRODUCTION 
2.1 
Background 
Inflammatory bowel diseases such as UC, CD, and non-specific colitis are chronic autoimmune 
diseases with significant unmet medical need.  Manifestations of the disease are unpredictable 
and can be progressive and, in certain cases, may result in life-threatening complications.  
Current small molecule therapies result in mainly symptomatic relief and current biologic 
therapies result in sustained remission in less than 25% of UC and 50% of CD patients, 
respectively.1,2  All treatment options are associated with significant safety concerns, notably 
increased infection risk due to sustained immune suppression.3  New treatment options are 
needed as surgical resection of the bowel remains a necessary intervention for a substantial 
portion of patients even after the introduction of biologic agents as treatments.  Since the 
introduction of newer agents (2003-2011), the rates of surgery for patients with CD and UC have 
decreased, but remain at ~20% and ~8%, respectively.4  Thus, there is a need for novel oral 
treatment options that will result in induction of remission as well as maintenance of remission 
over long-term dosing, with a reduced risk for immune suppression. 
The rationale for assessing LYC-30937-EC starts with accumulating evidence that lymphocytes 
adopt a specific metabolic phenotype that supports their particular effector function.  Thus, the 
energy required for normal lymphocyte activation is driven by aerobic glycolysis, whereas 
chronically activated pathogenic lymphocytes make their adenosine triphosphate (ATP) 
primarily via oxidative phosphorylation (OXPHOS) occurring in the mitochondria.5,6  OXPHOS 
is, in turn, dependent on the activity of the mitochondrial ATP synthase enzyme (F1F0-ATPase) 
that constitutes the final complex in the mitochondrial respiratory chain and is responsible for the 
formation of ATP.7,8  Modulation of the F1F0-ATPase (ATPase) with small molecule allosteric 
agents such as LYC-30937 (ATPase modulators) has demonstrated increases in reactive oxygen 
species and hyperpolarization of the mitochondrial membrane, changes that, together with other 
bioenergetic and redox abnormalities, result in apoptosis of susceptible cells.  ATPase 
modulators, therefore, selectively deplete chronically activated pathogenic lymphocytes while 
sparing normal lymphocytic function based on the distinct role of the ATPase in the differential 
metabolism of these lymphocyte subsets.  In agreement with this mechanism of action, ATPase 
modulators have demonstrated efficacy in several preclinical rodent models of autoimmune 
disease (arthritis, lupus, psoriasis, graft-versus-host disease, and IBD) with no effect on normal 
immune responses (no effect on primary or secondary responses in murine T-Cell-Dependent 
Antibody Response and adoptive transfer immunization models).9,10,11,12  
LYC-30937-EC is an orally administered EC small molecule ATPase modulator under 
development for treatment of IBD.  LYC-30937 acts as a potent immune modulator through 

 
Clinical Protocol 
LYC-30937-2002 
Amendment 2, 22 November 2016 
 
Confidential and Proprietary 
Page 12 of 56 
induction of cell death in chronically activated pathogenic lymphocytes and demonstrates 
efficacy in acute and chronic rodent models of colitis.  Moreover, LYC-30937 distributes 
preferentially to the colon versus plasma at efficacious doses in these models and is therefore 
predicted to work predominantly through local effects in the gastrointestinal tract, with limited 
systemic exposure.   
In initial dosing in healthy subjects, the PK profile in single ascending doses (SAD) was 
consistent with post-pyloric delivery (due to enteric coating) and the systemic exposures did not 
exceed 5.1 ng/mL, which is 50-fold below the no observed adverse effect level (NOAEL) in the 
rat, the most sensitive species.  In the multiple ascending dose (MAD; 100 and 200 mg dose 
groups) part of the study, the time of maximum observed plasma concentration (tmax) (> 4 hours) 
was also consistent with colonic delivery.  Furthermore, after multiple dosing, the area under the 
concentration-time curve from time 0 to 24 hours (AUC0-24) in the 100 mg dose group increased 
from 25.4 ng·h/mL at Day 1 to 99.5 ng·h/mL on Day 7, and from 62.7 ng·h/mL at Day 1 to 
173 ng·h/mL at Day 7 in the 200 mg dose group.  The highest individual plasma concentration in 
the 200 mg dose group (Cmax:  21.4 ng/mL; AUC0-24:  306 ng·h/mL) was still 10-fold below the 
NOAEL.   
In the Phase 1 study in UC patients, the AUC and Cmax were very similar to healthy volunteers 
following a single administration of a single dose of 25 mg.  At a dose of 100 mg, exposures 
were higher in UC patients; however, there were no safety findings and exposures remained at 
least 20-fold (based on Cmax and AUC) below the lowest NOAEL in the rat and monkey chronic 
toxicology studies.   
In summary, LYC-30937-EC is a first-in-class oral ATPase modulator with a novel mechanism 
of action that is anticipated to demonstrate clinical efficacy free from generalized immune 
suppression.  Overall, this profile could provide significant advantages for the treatment of IBD.   
2.2 
Rationale for the Study 
Inflammatory bowel disease is a complex autoimmune disorder that consists of UC, CD, and 
non-specific colitis that remains a disease of high unmet medical need.  Current therapies are 
limited by either low response rates or poor tolerability.  LYC-30937-EC has a unique 
mechanism of action, which results in induction of apoptosis in chronically activated 
lymphocytes such as those thought to drive the inflammation of UC.  LYC-30937 demonstrated 
efficacy in animal models of IBD and selective induction of apoptosis in chronically activated 
human lymphocytes.  LYC-30937-EC has also shown safety, tolerability, and a favorable PK 
profile in healthy volunteers up to single doses of 300 mg and 7 days of daily dosing at 200 mg, 
which are the highest doses tested in humans to date.  LYC-30937-EC has also been given to 

 
Clinical Protocol 
LYC-30937-2002 
Amendment 2, 22 November 2016 
 
Confidential and Proprietary 
Page 13 of 56 
subjects with UC in single doses of 25 and 100 mg and safety, tolerability, and a favorable PK 
profile was observed.  The mechanism of action of selective induction of apoptosis in chronically 
activated lymphocytes, the demonstration of efficacy in IBD models and the safety, tolerability, 
and PK profile demonstrated in the Phase 1 program supports further study of the compound in 
humans with IBD.  
Because of the above stated background and rationale for evaluation, LYC-30937-EC will be 
assessed in a separate Phase 2 double-blind, placebo-controlled study (Protocol LYC-30937-
2001).  The here described open-label extension (OLE) study is a follow-on extension to that 
double-blind study and will allow subjects who complete the LYC-30937-2001 study the 
opportunity to receive active treatment with open-label (OL) LYC-30937-EC and to obtain 
additional information on safety and tolerability of LYC-30937-EC in subjects with UC.  
2.3 
Nonclinical Studies 
2.3.1 
Nonclinical Pharmacology 
LYC-30937 is an orally administered small molecule for the treatment of IBD.  It functions as an 
allosteric modulator targeting the mitochondrial ATP synthase, also known as the F1F0-ATPase.  
Compounds that modulate F1F0-ATPase activity increase superoxide formation and mediate 
apoptosis of susceptible cells via a well-characterized apoptotic signaling cascade.  Consistent 
with this mechanism of action, LYC-30937 slows the rate of ATP production in sub-
mitochondrial particles, increases reactive oxygen species (ROS) generation, and induces 
apoptosis in a lymphocyte cell line.  In addition, LYC-30937 induces apoptosis of gut-tropic 
T cells from subjects with IBD. 
LYC-30937 and other ATPase modulator compounds are efficacious in acute and chronic rodent 
colitis models.  Oral administration of LYC-30937 in rodent models of IBD is associated with a 
reduction in clinical signs and improvements in histology.  LYC-30937 was selected for 
advancement based on its in vitro potency, in vivo immunomodulatory activity, and a PK profile 
characterized by high local tissue concentrations in the gastrointestinal tract.  In rodent IBD 
efficacy studies, LYC-30937 was efficacious at doses where plasma drug levels were below 
concentrations anticipated to be efficacious based on biochemical and cellular assays.  In 
contrast, colonic drug levels exceeded the 50% inhibitory concentration (IC50) values in 
enzymatic and cellular assays.  These data suggest that efficacy was largely driven by drug in 
colon tissues rather than plasma. 

 
Clinical Protocol 
LYC-30937-2002 
Amendment 2, 22 November 2016 
 
Confidential and Proprietary 
Page 14 of 56 
2.3.2 
Nonclinical Pharmacokinetics 
LYC-30937 has low aqueous solubility and exhibits moderate apparent permeability in a Caco-2 
cell model.  Following administration of single oral doses of LYC-30937 as an emulsion in a 
lipid-based formulation, bioavailability is low to moderate in monkeys, mice, and rats 
(10%-38%).  Plasma LYC-30937 exposures were similar in normal and trinitrobenzene sulfonic 
acid (TNBS)-treated rats indicating that colitis did not alter the PK of the drug.  When 
administered as a powder blend in an EC capsule (the intended clinical formulation) to monkeys, 
the AUC0-24 of LYC-30937-EC is approximately 10% of that achieved using a lipid-based 
formulation.  In mouse, rat, and monkey, LYC-30937 exhibits low to moderate plasma clearance, 
low to moderate volume of distribution, and a long terminal elimination half-life.  Plasma protein 
binding is moderate in all species (13%-18% free). 
LYC-30937 is moderately stable in hepatocytes from rat and human, and poorly stable in 
hepatocytes from monkey.  Metabolite profiles are qualitatively similar across species and all 
human metabolites were produced in rat and monkey hepatocytes.  The major metabolic 
pathways included glucuronidation and hydroxylation.  In addition, a cyclodehydration product 
(LYC-53552) was observed that appears to be formed non-enzymatically.  Conversion of 
LYC-30937 to LYC-53552 also was observed in simulated gastric fluid, consistent with the 
compound’s known instability in the presence of acid.  LYC-30937 is not predicted to be a direct 
inhibitor of human cytochrome P450 enzymes (CYPs) but may be a weak time-dependent 
inhibitor of CYP 2D6.  LYC-30937 is unlikely to be associated with significant drug-drug 
interactions. 
2.3.3 
Safety Pharmacology and Toxicology 
LYC-30937 is not genotoxic and does not produce adverse central nervous system, pulmonary or 
cardiovascular effects in single dose safety pharmacology studies. In rats and monkeys dosed for 
up to 28 days with LYC-30937, there was no evidence of generalized immunosuppression.  
In the rat 28-day good laboratory practice (GLP) toxicology study, an AUC of  5800 ng·h/mL 
was associated with sporadic instances of mortality.  In the rat 91-day GLP toxicology study, the 
NOAEL was 10 mg/kg with a plasma AUC of 7750 ng∙h/mL (combined sex mean).  Since 
mortality was observed in previous studies at a lower AUC, the rat NOAEL across all studies 
was considered to be the mid dose in the 91-day of 3 mg/kg with a Cmax of 257 ng/mL and an 
AUC of 3060 ng∙h/mL.  In the 26-week chronic toxicology study, the NOAEL was also 3 mg/kg 
and was associated with a mean steady state Cmax of 240 ng/mL and an AUC0-24 of 
3000 ng∙h/mL. 

 
Clinical Protocol 
LYC-30937-2002 
Amendment 2, 22 November 2016 
 
Confidential and Proprietary 
Page 15 of 56 
Due to the mitochondrial mechanism of action of LYC-30937, a study was conducted to explore 
uncoupling as a potential cause of mortality in rats at high plasma drug levels.  As measured by 
indirect calorimetry, at doses ≥7 mg/kg, LYC-30937 produced dose-related increases in oxygen 
consumption and body temperature consistent with mitochondrial uncoupling.  At a tolerated 
dose, measurable and reversible increases were observed for both parameters. 
In the 28-day GLP monkey toxicology study, an exposure of 6340 ng∙h/mL in the male high dose 
group (30 mg/kg) was associated with dose-limiting emesis and diarrhea leading to euthanasia of 
the group following 16-18 days of dosing.  In surviving animals, complete recovery from these 
clinical signs occurred following a reversal period of 28 to 38 days.  The NOAEL in the 28-day 
monkey study was 10 mg/kg/day associated with an AUC of 4820 ng∙h/mL (combined sex 
mean).  In the 91-day GLP toxicology study, the NOAEL was 10 mg/kg with an AUC of 
2580 ng∙h/mL.  Likewise, in the 39-week chronic toxicology study in monkeys, the NOAEL was 
10 mg/kg and was associated with a mean Cmax of 281 ng/mL and a mean AUC0-24 of 
2760 ng∙h/mL. 
Comparing plasma drug levels at the NOAELs in the chronic rat and monkey toxicology studies 
to the efficacious exposure in a chronic TNBS-induced colitis model following an oral dose of 
0.3 mg/kg, exposure ratios are > 20 based on Cmax and > 50 based on AUC.  
Additional information is provided in the Investigator’s Brochure (IB).  
2.4 
Previous Human Experience 
LYC-30937-EC has been studied in two Phase 1 studies. 
The Phase 1a study was comprised of a SAD, MAD, and food effect (FE) component.  A total of 
57 healthy male subjects were randomized in the study, 34 subjects in the SAD component, 
16 subjects in the MAD component, and 7 subjects in the FE component.  A total of 40 subjects 
received LYC-30937-EC treatment (SAD = 21, MAD = 12, FE = 7). 
A total of 52 treatment emergent adverse events (TEAEs) were reported.  All TEAEs were of 
mild severity.  There were no deaths or SAEs reported and no discontinuations due to AEs in any 
components of the study.  A total of 6 TEAEs were considered by the investigator to be possibly 
related to study drug.  All of these TEAEs were reported in the SAD component of the study, of 
which 5 TEAEs were reported by 3 placebo subjects and 1 TEAE (flatulence) by a subject 
receiving a single dose of 75 mg LYC-30937-EC. 

 
Clinical Protocol 
LYC-30937-2002 
Amendment 2, 22 November 2016 
 
Confidential and Proprietary 
Page 16 of 56 
There were no clinically significant findings with respect to clinical laboratory, vital signs 
(including body temperature), ECGs, continuous cardiac monitoring, PE, respirometry, and 
tissue or pulse oximetry.  
In the SAD component of the study, the Cmax reached a plateau of 3 to 4 ng/mL at the 75 mg 
dose cohort (at least 60-fold below the NOAEL in rats, the most sensitive species) and the AUC 
began to plateau at the 150-mg dose.  In the MAD component of the trial, the mean Cmax and 
AUC values were 10.3 ng/mL and 173 ng∙h/mL on Day 7 following oral administration of 
200 mg.  The extent of accumulation following multiple dosing was 3- to 4-fold.  
In the FE component of the study, administration of a single 100-mg dose under fed conditions 
resulted in a 15-fold increase in mean Cmax and a 6-fold increase in mean AUC versus the fasting 
exposures.  The highest individual exposure in a fed subject was 2- to 3-fold below the NOAEL 
in the rat, the most sensitive species.  
The Phase 1b study was an OL, SAD study to evaluate the PK profile, safety, and tolerability in 
subjects with UC.  A total of 6 subjects received LYC-30937-EC treatment at either 25 mg 
(3 subjects) or 100 mg (3 subjects).  No AEs were reported for the study and exposures at the 
25-mg dose were comparable to exposures in healthy volunteers.  At a dose of 100 mg, 
exposures were higher in UC subjects but there were no associated safety findings and exposures 
remained at least 20-fold (based on Cmax and AUC) below the lowest NOAEL in rat and monkey 
chronic toxicology studies.  
Overall, oral administration of LYC-30937-EC as single dose up to 300 mg and as once daily 
dose up to 200 mg for 7 days was safe and well tolerated.  Administration of a single, 100-mg 
dose under fed conditions in the FE component of the study demonstrated a significant food 
effect.  The increased exposures were not associated with any safety findings. 
Additional information can be found in the current LYC-30937 IB. 
2.5 
Dose Selection Rationale 
The proposed dose to be used in this trial is 25 mg daily oral dose, which is the same dose being 
used in the companion double-blind trial (LYC-30937-2001).  The rationale for this is based on 
the exposures required to demonstrate efficacy in the chronic TNBS IBD mouse model, and the 
safety margins for both the fasted and fed states. 
From the SAD study, a dose of 25 mg was associated with a Cmax of 1.7 ng/mL and the AUC0-72 
was 31.5 ng·h/mL.  Projection of steady-state exposure was based on the average accumulation 
observed following doses of 100 or 200 mg and using linear regression in relation to other doses 

 
Clinical Protocol 
LYC-30937-2002 
Amendment 2, 22 November 2016 
 
Confidential and Proprietary 
Page 17 of 56 
studied.  Using these methods, the steady-state Cmax and AUC following daily doses of 25 mg are 
projected to be approximately 2 ng/mL and 40 ng·h/mL, respectively.  Both the Cmax and AUC 
values exceed the exposures achieved in the mouse chronic TNBS model at 0.03 mg/kg where 
Cmax was 1 ng/mL and AUC0-24 was ≤ 10 ng·h/mL.  Furthermore, the colon tissue concentration 
of the compound is predicted to be at least 13-fold higher than in plasma, which will ensure 
adequate exposures at the site of action: chronically activated lymphocytes in the lamina propria.   
The 25-mg dose is also to ensure safety.  Subjects in this trial will be instructed to take study 
drug in the fasted state.  In the fasting state, the Cmax and AUC are projected to be > 100-fold 
below and > 70-fold below the rat NOAEL, respectively.  In the fed state, where there is 
significantly increased systemic exposure, exposures are projected to remain 10-fold below the 
lowest exposure associated with mortality in rats, the most sensitive species.   
Thus, the selection of the 25 mg daily dose is intended to provide the optimal benefit-to-risk 
profile.  This is achieved by the mechanism of delivering drug to the site of action while 
minimizing the systemic exposures.   
2.6 
Risks and Benefits 
Based on the results from the first-in-human study described in Section 2.4, single doses of up to 
300 mg were proven to be safe and well tolerated (in the SAD part of the study) and exposures 
observed with once daily dosing for 7 days in 100 and 200 mg dose groups in the MAD part of 
the study were similar to those observed in the SAD part of the study.   
The EC capsule was developed to deliver study drug to luminal tissue in the ileum and colon.  In 
addition, LYC-30937 is sparingly soluble in water and distributes preferentially to the colon 
versus plasma.  It is therefore predicted to work predominantly through local effects in the 
gastrointestinal tract, with limited systemic exposure.  It should be noted that with any clinical 
study drug, there is a risk of AEs.  Based on the human exposures in the Phase 1 study in healthy 
subjects and in the Phase 1b study in subjects with active UC, there were no safety signals 
detected.  There were no clinically significant laboratory abnormalities and the subjects tolerated 
the drug well.   
In Phase 2, the subjects will be suffering from active UC.  They will also be administered study 
drug for 8 weeks.  Subjects will be closely monitored for any potential AE or laboratory 
abnormality that may arise.  Because of the effect of a high fat meal on absorption, observed in 
the FE component of the Phase 1 study, subjects will be instructed to take their study drug upon 
awakening in the morning after fasting overnight.  They should not eat until approximately 
1 hour after taking study drug.  The Phase 2 double-blind study (LYC-30937-2001), that subjects 

 
Clinical Protocol 
LYC-30937-2002 
Amendment 2, 22 November 2016 
 
Confidential and Proprietary 
Page 18 of 56 
will complete before entering this OLE study will employ a data safety monitoring committee to 
provide additional safety oversight.  
The benefits of the study drug in subjects with active UC are being evaluated in this study, 
therefore any benefit is theoretical at this point in time.  There have been no previous efficacy 
studies prior to the Phase 2 double-blind study and this extension study.  The rationale to study 
this drug in subjects with UC is based on the mechanism of action of LYC-30937 and preclinical 
animal models of IBD. 
3.0 
STUDY OBJECTIVES AND ENDPOINTS  
3.1 
Study Objectives 
3.1.1 
Primary Study Objective  
The primary objective will be to evaluate the safety and tolerability of LYC-30937-EC in 
subjects with UC. 
3.1.2 
Exploratory Objective 
An exploratory objective will be to assess symptoms of UC for up to 44 weeks.  
3.2 
Endpoints 
3.2.1 
Safety Endpoint: 
 The incidence and type of AEs, SAEs, and AEs that led to discontinuation of treatment, 
laboratory assessments, vital sign measurements, ECGs, and PEs. 
3.2.2 
Exploratory Endpoint: 
 The change in Mayo stool frequency subscore at Weeks 4, 8, 20, 32, and 44 as compared to 
the study LYC-30937-2001 Week 8 stool frequency subscore  
 The change in Mayo rectal bleeding subscore at Weeks 4, 8, 20, 32, and 44 as compared to 
the study LYC-30937-2001 Week 8 rectal bleeding subscore 

 
Clinical Protocol 
LYC-30937-2002 
Amendment 2, 22 November 2016 
 
Confidential and Proprietary 
Page 19 of 56 
4.0 
STUDY DESIGN 
4.1 
Design Overview 
This study is a Phase 2 multicenter, multinational, OLE study designed to evaluate the safety and 
tolerability of LYC-30937-EC in subjects with UC.  Eligible subjects are male and female adult 
subjects who completed study LYC-30937-2001 and who meet the eligibility criteria as per the 
inclusion and exclusion criteria (see Sections 4.4.1 and 4.4.2, respectively).   
There are 3 distinct phases of this study as outlined below: 
Eligibility:  Eligibility is determined at Visit 6/Week 8 of the double-blind study LYC-30937-
2001.  Subjects who meet all eligibility requirements, including completing the LYC-30937-
2001 Visit 6/Week 8 procedures including endoscopy, will be dispensed OL study drug and 
instructed to start taking OL study drug the following morning.   
Open-Label Treatment Period:  Subjects will receive LYC-30937-EC 25 mg q.d.  Subjects 
will return to the clinic at Weeks 2, 4, 6, 8, 20, 32, and 44 for completion of the assessments 
detailed in the schedule of events (Table 1).   
Follow-Up: There will be 1 follow-up visit performed at Week 46 for final safety monitoring 
purposes.  
Therefore, all subjects will be followed for approximately 46 weeks, which includes 44 weeks 
for treatment and 2 weeks for follow-up.   
The assessments planned at each visit are detailed in the schedule of events (Table 1). 
4.2 
Number of Subjects and Sites 
Up to approximately 120 subjects may receive OL study medication at up to approximately 
66 sites.  The 3-digit site number will remain the same as that assigned in study LYC-30937-
2001. 
4.3 
Assignment of Subject Numbers 
Subjects will retain the same 6-digit unique identification number that they received in study 
LYC-30937-2001.  Subject identification numbers will be captured on the case report forms 
(CRFs) and will serve as the primary method of identifying each subject on the CRFs and on the 

 
Clinical Protocol 
LYC-30937-2002 
Amendment 2, 22 November 2016 
 
Confidential and Proprietary 
Page 20 of 56 
site’s source documents throughout the study.  Each site will prepare and maintain a “Master 
List” of each subject participating in the study. 
4.4 
Subject Selection 
The following entry criteria are designed to select subjects for the study for whom protocol 
treatment is considered appropriate.  All relevant medical and nonmedical conditions should be 
taken into consideration when deciding whether this protocol is suitable for a particular subject. 
4.4.1 
Inclusion Criteria 
Each of the following inclusion criteria must be met for entry into the study.   
1. 
Completed the 8-week double-blind treatment period of study LYC-30937-2001. 
2. 
Males and females of childbearing potential must agree to use adequate birth control 
measures during the study. Female subjects of childbearing potential must use 
2 highly effective forms of contraception, unless surgically sterilized, partner has had 
a vasectomy, or they will be abstinent during study participation and for 30 days after 
their last dose of study drug.  Highly effective methods of birth control in this study 
include:  intrauterine device, hormonal contraceptives (oral, patch, long acting 
injectable, implant), double-barrier method (condom or diaphragm with spermicide).  
3. 
Non-pregnant, non-lactating females who are not planning to become pregnant while 
enrolled in this study. 
4. 
Investigator considers it safe and potentially beneficial to participate. 
5. 
Ability to provide written informed consent and to be compliant with the schedule of 
events, provided in Section 6.2. 
4.4.2 
Exclusion Criteria 
Subjects presenting with any of the following will not participate in this study:  
1. 
Subjects who completed LYC-30937-2001, but who experienced an SAE that was 
considered related to investigational product (IP), or have an unstable medical 
condition, or for any other reason, in the opinion of the investigator, should not 
participate in this study. 

 
Clinical Protocol 
LYC-30937-2002 
Amendment 2, 22 November 2016 
 
Confidential and Proprietary 
Page 21 of 56 
4.5 
Subject Withdrawals 
Subjects will be encouraged to complete the study; however, they may voluntarily withdraw at 
any point during the study without prejudice.   
Subjects may be withdrawn from the study for the following reasons:  
 occurrence of any AE (if the subject withdraws due to an AE, the investigator should follow 
the subject until the AE resolves or stabilizes), concurrent illness, laboratory abnormality or 
other concern, which, in the opinion of the investigator or Lycera, warrants the subject’s 
permanent withdrawal  
 subject noncompliance, defined as refusal or inability to adhere to the study schedule or 
procedures 
 at the request of the subject (withdraw consent) 
 at the request of the investigator, Lycera (Sponsor), or regulatory authority(ies) for safety, 
behavioral, or administrative reasons  
 subject is lost to follow-up; if a subject does not return for a scheduled visit, every effort 
should be made to contact the subject and/or the subject’s family.  This effort must be clearly 
documented, or   
 Other (eg, subject moved) 
If a subject withdraws for any reason before completing Visit 8 (Week 44) every effort should be 
made to have the subject undergo final visit safety procedures at Visit 8/Week 44.  The 
investigator or site staff should inquire about the reason for withdrawal and follow-up with the 
subject regarding any unresolved AEs.  The reason for the withdrawal will be documented in the 
source documents and in the appropriate CRF.  
If a subject withdraws from the study, and withdraws consent for disclosure of future 
information, no further evaluations should be performed and no additional data should be 
collected.  Lycera may retain and continue to use any data collected before such withdrawal of 
consent. 

 
Clinical Protocol 
LYC-30937-2002 
Amendment 2, 22 November 2016 
 
Confidential and Proprietary 
Page 22 of 56 
5.0 
STUDY TREATMENTS 
5.1 
Description 
 Active Substance:  LYC-30937 
 Activity:  Modulator of mitochondrial F1F0 ATPase 
 Indication:  UC 
 Strength:  25 mg 
 Dosage Form:  Oral, delayed release, EC hydroxyl-propyl methyl-cellulose (HPMC) capsule 
 Manufacturer:  QS Pharma (Boothwyn, USA) 
5.2 
Treatment Regimen 
LYC-30937-EC will be administered orally q.d. from Study Day 1 through Visit 8/Week 44.  
The capsules must be administered in the morning upon awaking after fasting overnight.  Subject 
should not eat for approximately 1 hour (or more) after taking study drug.  Subjects will take 
their first dose the morning after the LYC-30937-2001 Visit 6/Week 8 study visit, which is the 
visit at which OL study drug is dispensed.   
 LYC-30937-EC 25 mg q.d.:  one 25-mg capsule of LYC-30937-EC, administer upon 
awaking in the morning after fasting overnight and do not eat within the next approximately 
1 hour after dosing.  
At the clinic, the study drug supplies must be handled and stored safely and properly, and kept in 
a secured location to which only the investigator and authorized staff have access. 
5.3 
Drug Supplies 
5.3.1 
Packaging and Labeling 
All study drug will be supplied in bottles.  
All manufacturing, packaging, and labeling operations will be performed according to Good 
Manufacturing Practices for Medicinal Products and the relevant regulatory requirements. 

 
Clinical Protocol 
LYC-30937-2002 
Amendment 2, 22 November 2016 
 
Confidential and Proprietary 
Page 23 of 56 
The study drug is to be dispensed according to the protocol.  The distribution will only occur 
after all required documentation is obtained including study approval by the Competent 
Authorities and the Institutional Review Board (IRB)/Independent Ethics Committee (IEC). 
Each bottle will be identified with a unique number.  The subject will be given bottles containing 
sufficient capsules for the subject until the next scheduled study visit.  The bottles will be labeled 
according to local requirements.   
5.3.2 
Product Accountability, Storage, Dispensing and Return 
Upon receipt of the study drug, the investigator or authorized designee will inspect the amount 
and condition of the medication, review for appropriate language in the label, and acknowledge 
receipt and condition in the interactive web-based response system (IWRS).  All study drug 
supplies will be stored in a locked and secure location accessible only to those authorized by the 
investigator to dispense the study drug.  The study drug supply will need to be stored under 
controlled room temperature conditions (15C-25°C / 59-77°F).  A detailed inventory log of 
study drug received and dispensed will be maintained by the investigator or authorized designee.  
During each study visit, the subject will receive a new medication supply containing sufficient 
study drug for the period until the next visit. 
A study drug accountability record will be maintained by the study site.  The investigator will 
not destroy unused study drug unless Lycera or designee provides written authorization.  
5.3.3 
Treatment Compliance 
Subject compliance with taking study drug will be assessed by counting the number of returned 
capsules at each visit.  Subjects should take study drug as directed by the investigator. Subjects 
should not stop or interrupt study drug on their own unless they experience an adverse event and 
in this case they should be instructed to contact the investigator immediately. The investigator 
(or designee) must complete the appropriate CRF pages to document the data.  
Subjects will return any unused study drug and empty bottles at each study visit and/or early 
discontinuation visit (if applicable).  Missed doses should be discussed to try to ascertain the 
reason(s).  Every effort should be made to ensure proper subject dosing. 
All unused study drug and empty bottles will be returned to the study drug supplier/contract 
research organization (CRO) depot as applicable at the closure of the study site or will be 
destroyed at the site, upon Sponsor decision.   

 
Clinical Protocol 
LYC-30937-2002 
Amendment 2, 22 November 2016 
 
Confidential and Proprietary 
Page 24 of 56 
5.4 
Concomitant Medications 
Subjects will not be permitted to use biologics and immunomodulatory medications during the 
study.  Subjects are allowed to remain on oral aminosalicylic acid (ASA) products that they were 
receiving during the double-blind study LYC-30937-2001.  Decrease of the corticosteroid use is 
allowed during this OL study using a tapering regimen per best clinical practice by the 
investigator.  If tapering is initiated, the daily dose of prednisone (or equivalent) should not be 
decreased by more than 5 mg per week until reaching 10 mg, then not more than 2.5 mg per 
week until discontinuation.  Subjects will not be permitted to use newly prescribed or increased 
dosages of ASA products or oral or injectable corticosteroids.  Also, rectal preparations of 
corticosteroids are not permitted.  Inhaled or topical corticosteroids are permitted to be used as 
medically indicated.  
Apart from the above, subjects are allowed any medications necessary for the treatment of 
concomitant medical disorders as deemed necessary by the treating physician and according to 
standard practice guidelines.  No therapeutic interventions that the investigator feels are 
clinically indicated will be withheld, independent of whether those compounds, procedures, or 
therapies were excluded in the eligibility criteria.  Following randomization, addition of 
concomitant medications or any change in the dosage should be limited to those considered 
medically essential.  All concomitant medication administration should be recorded as specified 
on the CRF.  
6.0 
STUDY PROCEDURES 
6.1 
Visit Timing 
The schedule of study assessments is described below (Table 1); however, a subject may be seen 
at any time for safety reasons.  Routine clinic visits outlined in the protocol should occur 
whenever possible at the same time of day throughout the study to decrease variation in 
assessments and procedures.  Prior to each clinic visit, subject activities should remain consistent 
with their normal routine (eg, meals, medications, caffeine ingestion).  Subjects should take 
prescribed and over-the-counter medications at the same time of the day throughout the study. 
 The day the subject receives the first dose of study drug is considered Study Day 1.  The 
timing of all study visits should be based on Study Day 1.   
 Study visit timing and windows are as follows: 
 Visit 1 (Study Day (-)1)  

 
Clinical Protocol 
LYC-30937-2002 
Amendment 2, 22 November 2016 
 
Confidential and Proprietary 
Page 25 of 56 
 Visit 2 (Week 2 – Study Day 14) – window ± 3 days  
 Visit 3 (Week 4 – Study Day 28) – window ± 3 days  
 Visit 4 (Week 6 - Study Day 42) – window ± 3 days  
 Visit 5 (Week 8 – Study Day 56) – window ± 3 days 
 Visit 6 (Week 20 – Study Day 140) – window ± 4 days 
 Visit 7 (Week 32 – Study Day 224) – window ± 4 days 
 Visit 8 (Week 44 – Study Day 308) – window ± 4 days 
 Visit 9 (Week 46 – Study Day 322) – window ± 4 days 
Unplanned visits may occur at any time for reasons of safety.  These visits and associated 
procedures must be documented on a CRF. 

 
Clinical Protocol 
LYC-30937-2002 
Amendment 2, 22 November 2016 
 
Confidential and Proprietary 
Page 26 of 56 
6.2 
Schedule of Events 
Table 1 
Schedule of Events 
Protocol Activity 
Eligibility and 
1st Dose a 
Treatment 
Follow-up 
 
 
Week 2 
Week 4 
Week 6 
Week 8 
Week 20 
Week 32 
Week 44 
Week 46 
OLE Study Day  
(-)1  
14 ± 3 days 
28 ± 3 days 
42 ± 3 days 
56 ± 3 days 
140 ± 4 days 224 ± 4 days 308 ± 4 days 
322± 4 days 
Visit Number 
1 a 
2 
3 
4 
5 
6 
7 
8 
9 
Informed consent 
X 
 
 
 
 
 
 
 
 
Assess OLE protocol 
eligibility 
X 
 
 
 
 
 
 
 
 
Dispense study drug using  
IWRS 
X i 
X 
X 
 
X 
X 
X 
 
 
Review study drug 
compliance 
 
X 
X 
X 
X 
X 
X 
X 
 
Dispense temperature log 
(to record body 
temperature taken by 
subjects during 1st week of 
dosing)  
X j  
 
 
 
 
 
 
 
 
Telephone reminder to 
subject regarding fasted 
dosing and body 
temperature monitoring  
X k 
 
 
 
 
 
 
 
 
Vital signs b 
 
X 
X 
X 
X 
X 
X 
X 
X 
Urine pregnancy test 
(women of childbearing 
potential only) 
 
X 
X 
X 
X 
X 
X 
X 
X 

 
Clinical Protocol 
LYC-30937-2002 
Amendment 2, 22 November 2016 
 
Confidential and Proprietary 
Page 27 of 56 
Table 1 
Schedule of Events 
Protocol Activity 
Eligibility and 
1st Dose a 
Treatment 
Follow-up 
 
 
Week 2 
Week 4 
Week 6 
Week 8 
Week 20 
Week 32 
Week 44 
Week 46 
OLE Study Day  
(-)1  
14 ± 3 days 
28 ± 3 days 
42 ± 3 days 
56 ± 3 days 
140 ± 4 days 224 ± 4 days 308 ± 4 days 
322± 4 days 
Visit Number 
1 a 
2 
3 
4 
5 
6 
7 
8 
9 
Weight 
 
X 
X 
X 
X 
X 
X 
X 
X 
Physical examination 
 
X 
X 
X 
X 
X 
X 
X 
X 
12-Lead ECG 
 
 
 
X 
 
 
 
X 
 
Dispense paper diary for 
collection of stool and 
rectal bleeding 
information 
X 
X 
X 
X 
X 
X 
X 
 
 
Stool frequency and rectal 
bleeding g 
 
X 
X 
X  
X 
X 
X 
X 
 
Telephone reminder to  
Subject to complete diary  
 
X h 
X h 
X h 
X h 
X h 
X h 
 
 
Chemistry panel c 
 
X 
X 
X 
X 
X 
X 
X 
X 
Hematology panel d 
 
X 
X 
X 
X 
X 
X 
X 
X 
Coagulation panel e 
 
 
X 
 
 
 
 
X 
 
Urinalysis f 
 
 
X 
 
 
 
 
X 
 
Concomitant medications 
 
X 
X 
X 
X 
X 
X 
X 
X 
Assess AEs 
 
X 
X 
X 
X 
X 
X 
X 
X 
AE = adverse event; ALT = alanine aminotransferase; ALP = alkaline phosphatase; AST = aspartate aminotransferase; BUN = blood urea nitrogen; CPK = 
creatine phosphokinase; ECG = electrocardiogram; ET = early termination; HDL = high-density lipoprotein; hsCRP = high sensitivity C-reactive protein; 
INR = international normalized ratio; LDH = lactate dehydrogenase; LDL = low-density lipoprotein; MCH = mean cell hemoglobin; MCHC = mean corpuscular 
hemoglobin concentration; MCV = mean corpuscular volume; OLE = open label extension; PT = prothrombin time; RBC = red blood cell; WBC = white blood 
cell. 

 
Clinical Protocol 
LYC-30937-2002 
Amendment 2, 22 November 2016 
 
Confidential and Proprietary 
Page 28 of 56 
a 
OLE Visit 1 (Study Day -1) is intended to occur at study LYC-30937-2001Visit 6/Week 8 after completion of all Visit 6 procedures. OLE eligibility will be 
assessed. Eligible subjects will have OLE medication dispensed and they will take their first dose the following morning which will be Study Day 1.  Refer 
to Section 6.2.1 for information related to situations when subjects enter the OLE study at a time later than at Visit 6/Week 8 of the double-blind study.  
b 
Vital signs will be collected at each clinic visit after the subject has been sitting quietly for ≥5 minutes and include blood pressure (systolic and diastolic), 
heart rate, respiratory rate and temperature.  
c 
Chemistry Panel includes: glucose, calcium, sodium, albumin, total protein, potassium, bicarbonate, chloride, BUN, creatinine, lactate, LDH, ALT, AST, 
reflexive bilirubin (total, direct, indirect), ALP, cholesterol, triglycerides, CPK, hsCRP, HDL, and LDL.    
d 
Hematology Panel includes: platelets, WBCs with differential if abnormal (% and absolute counts), hematocrit, RBCs, hemoglobin, MCV, MCHC, and 
MCH.  
e 
Coagulation Panel includes: PT, INR and fibrinogen.  
f 
Urinalysis (dipstick) includes: color, appearance, specific gravity, leukocyte esterase, pH, protein, glucose, ketones, blood, and nitrite. Microscopic 
urinalysis will be performed on samples with abnormal blood, leukocyte esterase, protein and nitrite.  
g 
Subjects will collect stool frequency and rectal bleeding in a paper diary on each of the 5 days immediately prior to the clinic visit starting at Visit 2.  Diaries 
will be dispensed at each visit through Visit 7/Week 32.  Note that at Visit 4/Week 6 stool and rectal bleeding information will be recorded in the source, but 
not in the eCRFs.  This information will be included in the eCRFs for all other visits. 
h 
Telephone subject approximately 7 days prior to the next visit to remind subject to record daily stool and rectal bleeding information on each of the 5 days 
prior to the next clinic visit.  
i 
The first dose of OLE study drug is to be taken the morning following the Visit 6/Week 8 double-blind visit at which drug is dispensed.  The first dose day 
will be Study Day 1.  
j 
Subjects will be instructed to take their body temperature approximately 4 and 8 hours after taking study drug during the first 7 days of dosing.  Subjects will 
be given a temperature log in which to record their body temperature and time of dosing for the first 7 days. 
k 
Telephone subject on Day 1 (first day of dosing) and again later during the first week of dosing to remind subject of dosing directions to take study drug 
after fasting overnight and not to eat for approximately 1 hour after taking study drug.  Also remind the subject to take their temperature each day, 
approximately 4 and 8 hours after dosing for the first 7 days of dosing and to call the investigator if their temperature is ever above 38.3°C/101°F. 

 
Clinical Protocol 
LYC-30937-2002 
Amendment 2, 22 November 2016 
 
Confidential and Proprietary 
Page 29 of 56 
6.2.1 
Eligibility Visit 1 
Visit 1 is intended to occur at the same clinic visit as Visit 6/Week 8 of the double-blind study 
LYC-30937-2001.  NOTE:  All Visit 6/Week 8 procedures (including endoscopy) must be 
completed before moving into the OLE.  Subjects who enter the OLE at the double-blind 
Visit 6/Week 8 will not complete the double-blind study Visit 7/Week 10 post-treatment follow-
up visit.  Subjects will have signed the OLE informed consent document (ICD) and will have 
met all eligibility criteria (specified in Sections 4.4.1 and 4.4.2).  They will retain the same 
subject identification number that they were assigned in double-blind study LYC-30937-2001. 
A subject who declines to participate in the OLE or who does not meet the eligibility criteria will 
not participate in any visits for this OLE study.  They should return for the Follow-up 
Visit 7/Week 10 of double-blind study LYC-30937-2001 to complete final safety assessments.   
Processes and procedures occurring during Eligibility Visit 1 are detailed below: 
 Inform subject of the OLE study details and obtain the subject’s signed ICD 
 Investigator confirms his/her eligibility and clinical belief that it is safe for subject to 
participate in OLE (refer to Inclusion and Exclusion Criteria in Sections 4.4.1 and 4.4.2) 
 Register visit in interactive web-based response system (IWRS), dispense study drug and 
instruct the subject to take their first dose the following morning.  Remind subjects to take 
1 capsule per day in the morning upon waking (fasting overnight), approximately 1 hour 
before eating 
 Dispense paper diary and instruct on its use for collection stool and rectal bleeding 
information 
 Dispense temperature log in which subjects will record their body temperature taken twice 
daily at approximately 4 and 8 hours after taking their dose of study drug on the first 7 days 
of dosing as well recording the time they take their study dose 
Post Visit 1 Telephone Follow-up Reminder with Subject – telephone the subject on Study Day 1 
(the day following Visit 1 and the first day of OLE study drug dosing) and a 2nd time during the 
first week of dosing following Visit 1 to remind the subject to take study drug on an empty 
stomach (fasted overnight) and to wait approximately 1 hour after dosing before eating.  Also 
remind subject to take body temperature approximately 4 and 8 hours after taking morning dose 
each day during the first week of dosing, to record the time study drug was taken and record 
temperatures in the log, and to call investigator immediately if body temperature is over 
101°F/38.3°C. 

 
Clinical Protocol 
LYC-30937-2002 
Amendment 2, 22 November 2016 
 
Confidential and Proprietary 
Page 30 of 56 
Reminder – site will telephone subject approximately 7 days prior to each subsequent visit to 
remind them to record daily stool and rectal bleeding information in the diary on each of the 
5 days prior to each visit.  
6.2.1.1 
Subjects Entering the OLE Study after Visit 6/Week 8 of the double-blind study  
Subjects who desire to participate in the OLE, but are unable to begin the OLE at double-blind 
study Visit 6/Week 8 for any reason should return and complete the double-blind study 
Visit 7/Week 10 follow-up visit.  They should start OLE study at this visit (preferred) or within 
the 3 weeks following completion of double-blind Visit 7/Week 10.  
 Subjects who start the OLE study at or within 3 weeks of completing double-blind study 
follow-up Visit 7/Week 10 will complete the procedures listed for Eligibility Visit 1 
(Section 6.2.1) and additionally should have the following performed: 
 Query for AEs since last visit 
 Review concomitant medication use  
 Subjects who start OLE study more than 3 weeks after completing double-blind study 
follow-up Visit 7/Week 10 will require agreement of the PI and the Medical Monitor.  If it is 
agreed that they may participate in the OLE, then the following additional procedures will be 
completed, except procedures listed for Eligibility Visit 1 (Section 6.2.1):  
 Obtain vital signs after sitting quietly for at least 5 minutes (includes systolic blood 
pressure [SBP], diastolic blood pressure [DBP], heart rate [HR], temperature [T], 
respiration rate [RR]) 
 Collect samples for chemistry and hematology laboratory analyses  
 Obtain sample for urine pregnancy test (women of childbearing potential only) 
6.2.1.2 
Subjects who transition from OLE Protocol Amendment 1 (issue date 23 August 
2016) to OLE Protocol Amendment 2 (issue date 22 November 2016) – applies to 
Netherlands, Hungary, and U.S. 
Subjects who first enroll in OLE protocol LYC-30937-2002 Amendment 1, designed with a 
4-week treatment period, may continue OLE study drug treatment in OLE protocol 
Amendment 2, which allows continued treatment up to 44 weeks.  When these subjects complete 
Visit 3/Week 4 of Amendment 1, they will then sign the revised informed consent for 

 
Clinical Protocol 
LYC-30937-2002 
Amendment 2, 22 November 2016 
 
Confidential and Proprietary 
Page 31 of 56 
Amendment 2 and will be dispensed study drug through IWRS and will proceed participating 
under Amendment 2 starting at Visit 4/Week 6. 
If OLE Protocol Amendment 2 has not yet received regulatory and/or EC/IRB approval at the 
time a subject completes Visit 3/Week 4 of Amendment 1, they should follow Amendment 1 
visit schedule and return and complete the follow-up Visit 4/Week 6.  Once the necessary 
regulatory and/or EC/IRB approvals are received the subject may re-start OLE study drug at 
Amendment 2 Visit 5/Week 8.   
6.2.2 
Visits 2, 3, 4, 5, 6, 7 (Weeks 2, 4, 6, 8, 20, 32) 
All subjects returning for these visits will complete the following procedures: 
 Obtain vital signs after sitting quietly for at least 5 minutes (includes SBP, DBP, HR, T, RR) 
 Measure weight 
 Conduct a PE 
 Perform 12-lead ECG (Visit 4/Week 6 only) 
 Collect stool frequency and rectal bleeding information from diary  
 Collect a serum sample for chemistry and hematology laboratory analysis 
 Collect a serum sample for coagulation laboratory analysis (Visit 3/Week 4 only) 
 Collect urine for urinalysis (Visit 3/Week 4 only) 
 Obtain urine sample for urine pregnancy test (women of childbearing potential only) 
 Review concomitant medication use 
 Query for AEs  
 Dispense paper diary for collection of stool and rectal bleeding information 
 Review compliance to OLE medication 
 Register visit in IWRS and dispense study drug  and remind subjects to take 1 capsule per 
day in the morning upon waking (fasting overnight) and to wait for approximately 1 hour 
before eating (registration in IWRS and drug dispensing are not done at Visit 4/Week 6) 
 Remind the subject to report any increases in body temperature and/or AEs 

 
Clinical Protocol 
LYC-30937-2002 
Amendment 2, 22 November 2016 
 
Confidential and Proprietary 
Page 32 of 56 
6.2.3 
Visit 8 or Early Termination (Week 44) 
All subjects returning for this visit will complete the following procedures: 
 Obtain vital signs after sitting quietly for at least 5 minutes (includes SBP, DBP, HR, T, RR) 
 Measure weight 
 Conduct a PE 
 Perform a 12-lead ECG 
 Collect stool frequency and rectal bleeding information from diary 
 Collect a serum sample for chemistry, hematology, coagulation laboratory analysis and a 
urine sample for urinalysis 
 Obtain urine sample for urine pregnancy test (women of childbearing potential only) 
 Review concomitant medication use 
 Query for AEs  
 Review compliance to OLE medication 
6.2.4 
Visit 9 Follow-Up (Week 46)  
All subjects returning for Visit 9 will complete the following procedures: 
 Obtain vital signs after sitting quietly for at least 5 minutes (includes SBP, DBP, HR, T, RR) 
 Measure weight 
 Conduct a PE 
 Collect a serum sample for chemistry and hematology analysis 
 Obtain urine sample for urine pregnancy test (women of childbearing potential only) 
 Review concomitant medication use 
 Query for AEs 
6.2.5 
Unplanned Visits 
Unplanned visits may occur at any time for reasons of safety.   

 
Clinical Protocol 
LYC-30937-2002 
Amendment 2, 22 November 2016 
 
Confidential and Proprietary 
Page 33 of 56 
6.3 
Subject Diary  
Subjects will use a diary to record their stools and rectal bleeding information.  Subjects will be 
requested to record this information daily on each of the 5 days prior to the clinic visits.  Site 
personnel will contact subjects approximately 7 days prior to the specified study visits to remind 
them to collect this diary information. This diary information will be recorded in the CRF 
(except at Visit 4/Week 6, when this information will only be collected in the subject source 
documents). 
6.4 
Safety Assessments Performed  
6.4.1 
Physical Examinations 
A PE will be conducted at the time points indicated in the schedule of events (Table 1). 
Standard PE will be performed by the Investigator or by an appropriately trained individual and 
will include a review of body systems outlined below.  
 General appearance 
 Head, eyes, ears, nose, and throat (HEENT) 
 Respiratory examination 
 Circulatory system 
 Abdominal examination 
 Musculoskeletal 
 Neurological examination to record the presence of abnormalities in mental status, motor, 
and sensory function (includes reflexes) 
 Any additional assessments necessary to establish baseline status or evaluate symptoms or 
adverse experiences 
Every effort should be made to have the same examiner perform each physical exam for a given 
subject to minimize variability in the examinations.  Clinically significant changes from 
screening should be noted as AEs. 
6.4.2 
Vital Signs Measurements 
Vital signs will be measured at the time points indicated in the schedule of events (Table 1). 

 
Clinical Protocol 
LYC-30937-2002 
Amendment 2, 22 November 2016 
 
Confidential and Proprietary 
Page 34 of 56 
Vital signs measurements consist of SBP, DBP, HR, RR, and T.  Subjects should sit quietly with 
feet flat on the floor or be supine (lying down) for at least 5 minutes prior to measurements. 
 Subject must remain seated or lying down for the entire measurement. 
 The use of automated devices for measuring blood pressure (BP) and HR is acceptable.  If 
done manually, HR must be measured in the brachial/radial artery following the site’s 
standard procedures.  Clinically significant changes from the subject’s baseline should be 
recorded as AEs.  
 BP determinations must be performed using calibrated and appropriately maintained 
equipment and the same equipment should be used on the same subject throughout the study 
as much as possible. 
 The same size BP cuff, which has been properly sized and calibrated, will be used to measure 
BP each time.  
 Subject’s arm should be at the same height (at the level of the heart) during each BP 
measurement.  
6.4.3 
12-Lead Electrocardiogram 
A 12-lead ECG will be conducted at the time points indicated in the schedule of events (Table 1). 
A standard 12-lead ECG will be performed after 5 minutes of rest in the supine position using a 
standardized automated device.  The following ECG parameters will be recorded:  HR, 
PR-interval, QRS-duration, QT-interval, QT interval corrected for heart rate according to 
Fredericia’s formula (QTcF)-interval and the investigator’s assessment of the ECG profile.  
Clinically significant changes from baseline should be recorded as AEs. 
6.4.4 
Laboratory Assessments 
Serum samples for laboratory assessments and urine samples for urinalysis will be collected at 
the time points indicated in the schedule of events and be analyzed by a central laboratory 
(Table 1).  The details on the serum and urine sampling procedures will be described in a 
separate laboratory manual.  
The investigator at the site must assess the clinical significance of all laboratory values outside 
the laboratory reference ranges.  All laboratory abnormalities considered to be clinically 
significant by the investigator should be repeated.  Confirmed, clinically significant laboratory 
abnormalities should be further evaluated by the investigator and captured as an AE. 

 
Clinical Protocol 
LYC-30937-2002 
Amendment 2, 22 November 2016 
 
Confidential and Proprietary 
Page 35 of 56 
Chemistry Panel Sample 
The chemistry panel includes:  glucose, calcium, sodium, albumin, total protein, potassium, 
bicarbonate, chloride, blood urea nitrogen (BUN), creatinine, lactate, alanine aminotransferase 
(ALT), aspartate aminotransferase (AST), reflexive bilirubin (total, direct, indirect), alkaline 
phosphatase (ALP); high sensitivity C-reactive protein (hsCRP), creatine phosphokinase (CPK), 
cholesterol, triglycerides, high-density lipoprotein (HDL), low-density lipoprotein (LDL), lactate 
dehydrogenase (LDH).   
Hematology Panel Sample 
The hematology panel includes: platelets, white blood cells (WBCs) with differential if abnormal 
(% and absolute counts), hematocrit, red blood cells (RBCs), hemoglobin, mean corpuscular 
volume (MCV), mean corpuscular hemoglobin concentration (MCHC), and mean cell 
hemoglobin (MCH).   
Coagulation Panel Sample 
The coagulation panel includes:  prothrombin time (PT), international normalized ratio (INR) 
and fibrinogen.   
Urine Sample (Dipstick) 
The urinalysis test includes:  color, appearance, specific gravity, leukocyte esterase, pH, protein, 
glucose, ketones, blood, and nitrites.  Microscopic urinalysis will be performed on samples with 
abnormal blood, leukocyte esterase, protein, and nitrite.  This test will be evaluated by dipstick at 
the central laboratory.   
Childbearing Potential Evaluation and Pregnancy Tests 
Urine pregnancy tests will be performed in women of childbearing potential (as established in 
study LYC-30937-2001) at the time points designated in the Table 1.  
6.4.5 
Body Temperature Monitoring 
Subjects are to take their body temperature at the time points indicated in the schedule of events 
(Table 1) (ie, approximately 4 and 8 hours after taking the study drug during the first week of 
treatment).  Subjects will record these temperatures and the time study drug is taken each day in 
a log and they’ll bring this completed log to study Visit 2. 

 
Clinical Protocol 
LYC-30937-2002 
Amendment 2, 22 November 2016 
 
Confidential and Proprietary 
Page 36 of 56 
If the subject’s temperature reading is > 101°F (or 38.3°C) they must call their investigator and 
this should be documented as an adverse event.   
If a subject calls with an elevated body temperature, the subject is to present to the clinic and be 
evaluated for a possible bacterial or viral infection.  This assessment is to be completed per the 
investigator’s best clinical judgment (eg, if there is suspicion of a urinary tract infection, then the 
subject is to have a urinalysis performed; if the subject has signs and symptoms of a classic viral 
upper respiratory tract infection, then the subject can be treated symptomatically without being 
evaluated).   
If there are no signs or symptoms of infection, then the subject is to present to the clinic.  The 
study drug should be withheld and the subject should be evaluated for other sources of increased 
temperature as medically indicated.  Study drug may be re-started if study drug has been 
interrupted for no more than 3 days and the source of the elevated temperature is determined, or 
it resolves, and in the clinical judgement of the investigator and Study Medical Monitor it is safe 
for the subject to continue study drug.  If the subject is off drug for more than 3 days the 
investigator should withdraw the subject from the study. 
6.4.6 
Monitoring Subjects for Adverse Events of Special Interest 
Subjects will be monitored throughout the study for the occurrence of AEs and for abnormal 
clinical laboratory values.   
AEs of special interest include those that may be related to LYC-30937’s mechanism of action of 
mitochondrial modulation and those AEs which may indicate hepatotoxicity. Investigators 
should be particularly mindful of these AEs, which include vomiting, abdominal pain, elevated 
lactate, and abnormal liver function tests indicative of possible hepatotoxicity (AST, ALT, total 
bilirubin, ALP, LDH).  Guidance for monitoring for these AEs of special interest is outlined 
below: 
Vomiting or Abdominal Pain: 
If a subject exhibits repeated episodes of vomiting or persistent abdominal pain above the 
severity and/or frequency they experience as part of their underlying UC, they must contact their 
investigator.  [Because UC subjects experience these symptoms as part of their disease, it is very 
important to understand and document at screening the “normal” severity and frequency of these 
symptoms for each subject].  They should present to the clinic as soon as possible to be evaluated 
for potential source of the symptom and liver function testing should be performed.  The study 
medical monitor should be contacted.  If a source is not readily identified then study drug should 

 
Clinical Protocol 
LYC-30937-2002 
Amendment 2, 22 November 2016 
 
Confidential and Proprietary 
Page 37 of 56 
be withheld and the subject should continue to be evaluated for the source and managed as 
medically indicated.  Study drug may be re-started if it has been interrupted for no more than 
3 days and the source of the vomiting or abdominal pain is determined, or if these symptoms 
resolve, and in the clinical judgement of the investigator and study medical monitor it is safe for 
the subject to continue study drug.  If the subject is off drug for more than 3 days the investigator 
should withdraw the subject from the study. 
Elevated Lactate and Liver Function: 
If a subject exhibits any of the following elevations, study drug should be withheld and the 
subject should be evaluated for cause:  
 ALT or AST > 8 x upper limit of normal (ULN) 
 ALT or AST > 5 ULN for more than 2 weeks 
 ALT or AST > 3 x ULN and total bilirubin > 2 x ULN (or INR > 1.5) 
 ALT or AST > 3 x ULN with appearance of fatigue, nausea, vomiting, right upper quadrant 
pain or tenderness, fever, rash and/or eosinophilia (> 5%) 
 ALP > 1.5 x ULN 
 Lactate ≥ 3 mmol/L 
 LDH > 2 x ULN 
If any of the above occur the investigator must contact the subject to request they stop taking 
study drug and report to the clinic as soon as possible for evaluation (do not wait for the next 
scheduled study visit).  As dehydration and heavy physical exertion can cause elevations (eg, of 
blood lactate levels), the clinical lab should be repeated with the subject instructed to ensure 
hydration and avoid heavy physical activity.  The study medical monitor should be contacted to 
discuss the subject. If the elevation is confirmed by repeat lab and neither dehydration nor 
physical exertion explains the elevation, study drug must continue to be withheld.  Close 
observation of the subject should be initiated.  Repeat liver enzyme and serum bilirubin testing 
should be performed 2 to 3 times weekly until values return to baseline.  Frequency of this 
retesting can decrease to once per week or less if abnormalities stabilize or the study drug has 
been discontinued and the subject is asymptomatic.  The investigator should obtain a detailed 
history of symptoms, prior or concurrent diseases, concomitant drug use, alcohol use, 
recreational drug use, special diets, and exposure to environmental chemical agents.  Evaluation 

 
Clinical Protocol 
LYC-30937-2002 
Amendment 2, 22 November 2016 
 
Confidential and Proprietary 
Page 38 of 56 
should be performed to rule out acute viral hepatitis types A, B, C, D, and E; autoimmune or 
alcoholic hepatitis; nonalcoholic steatohepatitis; hypoxic/ischemic hepatopathy; and biliary tract 
disease.  Obtain additional tests to evaluate liver function as appropriate (eg, INR, direct 
bilirubin). Consider gastroenterology or hepatology consults.  If a source of the abnormal value 
is not readily identified the subject should continue to be evaluated for the source and managed 
as medically indicated.  Study drug may be re-started if study drug has been interrupted for no 
more than 3 days and the source of the abnormal value(s) is determined, or if upon repeating the 
clinical lab the value returns to normal, and in the clinical judgement of the investigator and 
study medical monitor it is safe for the subject to continue study drug.  If study drug cannot be 
ruled out as the cause of the abnormal value then study drug should be permanently 
discontinued.  Additionally, if study drug is interrupted for more than 3 days, then study drug 
should be permanently discontinued.  
7.0 
ADVERSE EVENTS AND SAFETY MONITORING 
7.1 
Adverse Event Definition 
Defined by 21 Code of Federal Regulation (CFR) 312.32(a) and consistent with International 
Council for Harmonisation (ICH) E2A guidance, an AE means untoward medical occurrence 
associated with the use of a drug in humans, whether or not considered drug related.  An AE can 
be any unfavorable or unintended sign (eg, an abnormal laboratory finding), symptom, or disease 
temporally associated with the use of a drug, without any judgment about causality.  Examples of 
AEs include but are not limited to: 
 Abnormal test findings 
 Clinically significant symptoms and signs 
 Changes in physical examination findings 
 Hypersensitivity 
 Progression/worsening of underlying disease  
Events related to the underlying disease(s), which have not worsened in intensity (severity) or 
frequency since screening, are not AEs.   

 
Clinical Protocol 
LYC-30937-2002 
Amendment 2, 22 November 2016 
 
Confidential and Proprietary 
Page 39 of 56 
7.2 
Serious Adverse Events Definition 
Defined by 21 CFR 312.32(a) and consistent with ICH E2A guidance, an AE is considered 
“serious” if, in the view of either the investigator or Sponsor, it results in any of the following 
outcomes:  
 Death 
 Life threatening (ie, in the view of either the investigator or Sponsor, its occurrence places 
the subject at immediate risk of death.  It does NOT include an event, that had it occurred in 
a more severe form, might have caused death) 
 In-subject hospitalization or prolongation of existing hospitalization 
 Persistent or significant incapacity or substantial disruption of the ability to conduct normal 
life functions 
 Congenital anomaly/birth defect 
 Other medically significant events that, based upon appropriate medical judgment, may 
jeopardize the subject and may require medical or surgical intervention to prevent one of the 
outcomes listed above.  For example:  an allergic bronchospasm requiring intensive treatment 
in an emergency room or home, blood dyscrasias or convulsions that do not result in 
hospitalization, or the development of drug dependency 
7.3 
Adverse Event Reporting 
AEs, both serious and non-serious, should be collected on source documents from the time the 
subject has signed informed consent through last subject visit.  The investigator is to collect all 
directly observed AEs and all AEs spontaneously reported by the study subject.  In addition, 
each study subject will be questioned about AEs.  AEs should be recorded on CRFs from the 
time the subject takes their first dose of OL drug.  
Each AE is to be assessed to determine if it meets the criteria for SAE, see Section 7.2 above.  If 
an SAE occurs, expedited reporting will follow local and international regulations, as 
appropriate.   
AEs should be reported using concise medical terminology on the CRFs. The diagnosis should 
be recorded on the CRF, rather than recording individual signs and symptoms.  For example, 
congestive heart failure should be recorded rather than low ejection fraction, pedal edema, rales 

 
Clinical Protocol 
LYC-30937-2002 
Amendment 2, 22 November 2016 
 
Confidential and Proprietary 
Page 40 of 56 
and dyspnea.  However, if a diagnosis is known and there are other signs or symptoms that are 
not generally part of the diagnosis, the diagnosis and each sign or symptom not part of the 
diagnosis should be recorded separately, for example:  congestive heart failure and conjunctivitis 
should recorded as separate AEs.  
Diagnostic and therapeutic noninvasive procedures should not be reported as AEs.  However, the 
medical condition for which the procedure was performed should be reported if it meets the 
definition of an AE and procedure would be the treatment and recorded as “action taken” of the 
AE.   
For all AEs, the investigator must pursue and obtain information adequate both to determine the 
outcome of the AE and to assess whether it meets the criteria for classification as an SAE 
requiring immediate notification to Lycera or its designated representative.  For all AEs, 
sufficient information should be obtained to determine the causality of the AE.   
All AEs that occur from the time of informed consent, regardless of whether the particular event 
is expected and regardless of relatedness, will be recorded as an AE. 
7.4 
Assessment of Severity of Adverse Events 
The investigator or physician will assess subjects at each visit for the occurrence of AEs.  In 
order to avoid bias in eliciting AEs, subjects should be asked the following non-leading 
questions:  “How are you feeling?”  All AEs (serious and non-serious) reported by the subject 
must be recorded on the CRFs regardless whether a causal relationship to the study drug is 
suspected.   
Severity of AEs will be graded according to National Cancer Institute (NCI) Common 
Terminology for Adverse Events (CTCAE v4.03). 
Adverse events that are not included in the NCI CTCAE lists will be graded according to the 
NCI CTCAE general guideline for grades as follows: 
Grade 1 
Mild, asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated. 
Grade 2 
Moderate, minimal, local intervention, or noninvasive intervention indicated; 
limiting age-appropriate instrumental activities of daily living (ADL), eg, 
preparing meals, shopping for groceries or clothes, using the telephone, managing 
money. 

 
Clinical Protocol 
LYC-30937-2002 
Amendment 2, 22 November 2016 
 
Confidential and Proprietary 
Page 41 of 56 
Grade 3 
Severe or medically significant but not immediately life-threatening; 
hospitalization or prolongation of hospitalization indicated; disabling; limiting 
self-care ADL, eg, bathing, dressing and undressing, feeding self, using the toilet, 
taking medications, and not bedridden. 
Grade 4 
Life-threatening consequences; urgent intervention indicated. 
Grade 5 
Death related to AE 
Note the distinction between the severity and the seriousness of an AE.  A severe event is not 
necessarily a serious event.  For example, a headache may be severe (interferes significantly with 
subject’s usual function) but would not be classified as serious unless it met one of the criteria 
for SAEs, listed in Section 7.2.   
7.5 
Serious Adverse Event Reporting 
All observed or volunteered SAEs regardless of treatment group or suspected causal relationship 
to the study drug will be reported as described below.   
If an SAE occurs, ICON Pharmacovigilance and Safety Services (PVSS) is to be notified within 
24 hours of awareness of the event by the investigator or sub-investigator.  The initial SAE 
report form should be completed and sent to ICON PVSS using one of the following: 
North America: 
Email:  icon-mads@iconplc.com 
Facsimile:  +1-215-616-3096 
Telephone:  +1-888-723-9952 
Europe: 
Email:  icon-safety-centralreceipt@iconplc.com 
Facsimile:  +44-(0)208 100 5005 
In particular, if the SAE is fatal or life threatening, notification must be made immediately, 
irrespective of the extent of available AE information.   
This timeframe also applies to additional new information (follow-up) on previously forwarded 
SAE reports as well as to the initial and follow-up reporting of exposure in utero (EIU) cases.  
The investigator should continue to report any significant follow-up information to ICON PVSS 
up to the point of resolution.  

 
Clinical Protocol 
LYC-30937-2002 
Amendment 2, 22 November 2016 
 
Confidential and Proprietary 
Page 42 of 56 
In the rare event that the investigator does not become aware of the occurrence of an SAE 
immediately (eg, if an outpatient trial subject initially seeks treatment elsewhere), the 
investigator is to report the event within 24 hours after learning of it and document the time of 
his/her first awareness of the SAE. 
The study sponsor medical monitor will perform final medical review of SAEs. Full details of 
the SAE processing and review procedures will be documented in a safety management plan and 
a medical monitoring plan. Serious adverse events, including any deemed as suspected 
unexpected serious adverse reactions (SUSAR) will be reported according to timeframes as per 
country regulatory guidance, including to United States (US) Food and Drug Administration 
(FDA) within 15 calendar days of ICON PVSS notification and within 7 calendar days if the 
SUSAR is considered life threatening or resulted in death.  A serious adverse reaction is 
considered “unexpected” if it is not listed in the investigator brochure or is not listed at the 
specificity or severity that has been observed.  A serious adverse reaction is considered 
“unexpected” if it is not listed in the IB or is not listed at the specificity or severity that has been 
observed. Non-SUSAR SAEs will be reported to country regulatory authorities as per regulatory 
guidance. 
For all SAEs, the investigator is obligated to pursue and provide information to Lycera or 
designee in accordance with the timeframes for reporting specified above.  In addition, an 
investigator may be requested by Lycera to obtain specific additional follow-up information in 
an expedited fashion.  In general, the SAE form will include a description/narrative of the event 
in sufficient detail to allow for a complete medical assessment of the case and independent 
determination of possible causality.  Information on other possible causes of the event, such as 
concomitant medications and illnesses must be provided.  In the case of a subject death, a 
summary of available autopsy findings must be submitted as soon as possible to Lycera or its 
designated representative.  Expedited safety reports on all unexpected SAEs that are at least 
possibly related to study procedures will be provided to the FDA. 
Subjects with unresolved previously reported SAEs, or new SAEs identified on the last 
scheduled visit, should be followed by the investigator until the events are satisfactorily resolved.  
Resolution means the subject has returned to the baseline state of health, the investigator does 
not expect any further improvement or worsening of the AE, or upon agreement with Lycera or 
designee.   

 
Clinical Protocol 
LYC-30937-2002 
Amendment 2, 22 November 2016 
 
Confidential and Proprietary 
Page 43 of 56 
7.6 
Post-Week 46 Reporting of Serious Adverse Events 
Any SAEs reported by the subject to the investigator that occur after the last visit and are 
determined by the investigator to be associated with the use of LYC-30937-EC or with 
associated study procedures, should be reported to Lycera or designee.   
7.7 
Exposure in Utero (EIU) 
For IP within clinical trials, an EIU occurs if: 
 A female becomes, or is found to be, pregnant after receiving the IP.  
If any study subject becomes pregnant during their participation in the study, the subject will 
stop study drug and withdraw from the study.  The investigator must submit this information to 
Lycera or designee on EIU Form.  This must be done irrespective of whether an AE has occurred 
and within 24 hours of awareness of the pregnancy.  The information submitted should include 
the anticipated date of delivery (see below for information related to an induced termination of 
pregnancy).  
Follow-up is conducted to obtain pregnancy outcome information on all EIU reports with an 
unknown outcome.  The investigator will follow the pregnancy until completion or until 
pregnancy termination (ie, induced abortion) and then notify Lycera or designee of the outcome.  
The investigator will provide this information as a follow up to the initial EIU Form.  The 
reasons(s) for an induced abortion should be specified.  An EIU report is not created when an 
ectopic pregnancy report is received since this pregnancy is not usually viable, however such 
events should be considered as SAEs and the investigator should follow the procedures for 
reporting SAEs.  
If the pregnancy outcome meets the criteria for immediate classification as an SAE (ie, 
spontaneous abortion, stillbirth, neonatal death, or congenital anomaly [including resulting in an 
aborted fetus, stillbirth or neonatal death]), the investigator should follow the procedures for 
reporting SAEs.   
In the case of a live birth, the “normality” of the newborn can be assessed at the time of birth (ie, 
no minimum follow-up period of a presumably normal infant is required before an EIU Form can 
be completed).  The “normality” of an aborted fetus can be assessed by gross visual inspection, 
unless pre-abortion test findings are suggestive of a congenital anomaly.   

 
Clinical Protocol 
LYC-30937-2002 
Amendment 2, 22 November 2016 
 
Confidential and Proprietary 
Page 44 of 56 
Additional information about pregnancy outcomes that are classified as SAEs follows: 
 “Spontaneous abortion” includes miscarriage and missed abortion. 
 All neonatal deaths that occur within 1 month of birth should be reported, without regards to 
causality as SAEs.  In addition, any infant death after 1 month that the investigator assesses 
as possibly related to the in utero exposure to the investigational medication should be 
reported. 
7.8 
Relationship/Causality of Adverse Events/Serious Adverse Events 
The investigator’s assessment of causality must be provided for all AEs (serious and non-
serious).  The causality assessment is the determination of whether there exists a reasonable 
possibility that the study drug itself (eg, LYC-30937-EC) caused or contributed to an AE.   
If the final determination of causality is unknown and the investigator does not know whether the 
study drug caused the event, then the event will be handled as “related to study drug” for 
reporting purposes.  If the investigator’s causality assessment is “unknown, but not related to 
IP”, this should be clearly documented on study records and will be categorized as “not related to 
study drug” for reporting purposes.  
Relationship of an AE to the study drug will be assessed as follows: 
Unrelated [Not Related or Unlikely Related]:  There is not a temporal or causal relationship to 
the study drug.  If the AE is “unrelated” to the study drug, the investigator must assess whether 
the event is thought to be related to the disease under study, concomitant medication, 
exacerbation of pre-existing condition, other illness, or unknown. 
Related [Definite]:  There is reason to conclude that the study drug caused the AE.   
Suspected [Possible or Probable]:  There is evidence to suggest a causal relationship between 
the study drug and the AE.  For analysis purposes “Suspected [Possible or Probable]” events are 
considered “Related.”  
7.9 
Withdrawal Due to Adverse Events 
Withdrawal due to AEs must be recorded on the appropriate AE CRF page.  
When a subject withdraws due to an SAE, the SAE must be reported in accordance with the 
reporting requirements as defined. 

 
Clinical Protocol 
LYC-30937-2002 
Amendment 2, 22 November 2016 
 
Confidential and Proprietary 
Page 45 of 56 
7.10 
Medical Monitoring 
Medical monitoring of the study will be performed by Lycera or designee in cooperation with the 
investigator(s) at the participating sites.  Review of laboratory data, AEs, vital signs, PE data, 
and ECG data will be at regular intervals throughout the study.  When additional information is 
required, Lycera or designee will contact the investigator or designee. 
The sponsor Medical Monitor for the trial is: 
H. Jeffrey Wilkins, MD 
Lycera Corp. 
Plymouth Meeting, PA USA 
Office:  +1-484-243-6222 
Mobile:  +1-610-457-5095 
Facsimile:  +1-734-207-3178 
7.11 Stopping Rules 
The sponsor has the right to terminate the study prematurely for safety or administrative reasons.  
In all cases, necessary measures will be taken to ensure appropriate safety follow-up of all 
subjects in the trial.   
Individual subjects may interrupt or stop study drug at the discretion of the investigator or 
medical monitor any time for safety reasons.  Individual subjects must discontinue if they 
experience a study drug-related Grade 3 (CTCAE version 4.03) AE of special interest – see 
Section 6.4.6 for list of AEs of special interest.   
ECGs are scheduled to be performed at Week 6 and Week 44 (end of treatment).  An additional 
ECG should be performed if a subject reports symptoms of recurrent palpitations, recurrent, 
persistent lightheadedness or faintness, or any symptom that the investigator deems for cause.  
Subjects should report these symptoms to the investigator immediately and return to the clinic as 
soon as possible for evaluation including an ECG.  Subjects will discontinue study drug if 
marked QT/QTc prolongation of > 500 ms or > 60 ms over baseline is present.  
7.11.1 
Suspension of Study 
The study will be suspended if any subject experiences a study drug-related AE that meets 
Grade 4 or 5 CTCAE criteria or if 2 or more subjects experience a study drug-related Grade 3 
adverse event of the same type.  The unblinded medical reviewer will review these cases to 
determine treatment assignment.  Adverse event reports will be submitted to regulatory agencies 
and clearance received before any further dosing takes place.  

 
Clinical Protocol 
LYC-30937-2002 
Amendment 2, 22 November 2016 
 
Confidential and Proprietary 
Page 46 of 56 
The study will be suspended if 50% of subjects experience clinically important drug-related AEs 
with a determined intensity of CTCAE Grade 2.  The unblinded medical reviewer will review 
these cases to determine treatment assignment.  
8.0 
STATISTICAL AND ANALYTICAL PLAN 
8.1 
Analysis Populations 
8.1.1 
Safety Set 
The Safety Set is defined as all subjects who sign the OLE consent and received at least 1 dose 
of study drug in the extension study.  All safety analyses will be performed on the Safety Set.  
8.2 
General Statistical Considerations 
Continuous endpoints will be summarized using at least mean, standard deviation, median, 
minimum, and maximum.  Categorical endpoints will be summarized by the number and percent 
of subjects in each category. Additional details of the statistical analyses will be detailed in the 
statistical analysis plan (SAP). 
8.3 
Demographic and Subject Characteristics 
Demographic information and subject characteristics such as gender, race, age, baseline weight, 
baseline Mayo stool frequency and rectal bleeding subscores, treatment group in the double-
blind study, and whether or not the subject achieved clinical remission at Visit 6/Week 8 of the 
LYC-30937-2001 study will be listed and summarized.   
8.4 
Safety Analysis 
AE collection begins after the subject signs the ICD and continues until completion of post-
treatment follow-up Visit 9/Week 46. Open-label TEAEs are defined as AEs that start after OL 
study drug administration (LYC-30937-EC) and include worsening of conditions that existed 
prior to study drug administration.   
AEs, SAEs and AEs that led to discontinuation of treatment will be listed and summarized by 
system organ class, by severity, and by relationship.  SAEs resulting in death will be listed and 
summarized separately.  TEAEs and TESAEs will also be summarized by system organ class, by 
severity, and by relationship. 
Other safety data, such as physical examinations, vital signs, ECGs, clinical laboratory data, and 
body temperature will be listed and summarized by study visit.   

 
Clinical Protocol 
LYC-30937-2002 
Amendment 2, 22 November 2016 
 
Confidential and Proprietary 
Page 47 of 56 
Concomitant medications will be listed and summarized. 
8.5 
Exploratory Efficacy Analysis 
The Mayo stool frequency and rectal bleeding subscores will be listed and summarized by study 
visit.  Baseline stool frequency and rectal bleeding subscores will be those subscores obtained at 
Visit 6/Week 8 of double-blind study LYC-30937-2001.  
9.0 
ETHICAL CONSIDERATIONS 
9.1 
Basic Principles 
The study will be performed in accordance with the protocol, ICH Good Clinical Practice (GCP) 
guidelines, and applicable local regulatory requirements and laws. 
9.2 
Institutional Review Board / Independent Ethics Committee  
It is the responsibility of the investigator to have prospective approval of the study protocol, 
protocol amendments, informed consent forms, and other relevant documents, eg, 
advertisements, if applicable from the IRB or IEC.  All correspondence with the IRB/IEC should 
be retained in the Investigator File.  Copies of IRB/IEC approvals should be forwarded to Lycera 
or designee.   
9.3 
Informed Consent 
Written informed consent is to be obtained prior to the subject entering the study (before 
initiation of protocol-specified procedures).  The investigators, or other study personnel, explain 
the nature, purpose, and risks of the study to each subject.  Each subject is to be informed that 
he/she could withdraw from the study at any time and for any reason.  Each subject is to be given 
sufficient time to consider the implications of the study before deciding whether to participate.  
Subjects who chose to participate will sign an ICD. 
9.4 
Study Termination 
Premature termination of this study or part of the study may occur because of a regulatory 
authority decision, change in opinion of the IRB/IEC, safety problems, or at the discretion of 
Lycera.  In addition, Lycera retains the right to discontinue development of LYC-30937-EC at 
any time.   
If a study is prematurely terminated or discontinued, Lycera will promptly notify the 
investigator.  After notification, the investigator must notify all subjects currently participating in 

 
Clinical Protocol 
LYC-30937-2002 
Amendment 2, 22 November 2016 
 
Confidential and Proprietary 
Page 48 of 56 
the study within a specific timeframe designated by Lycera.  As directed by Lycera, study 
materials will be collected and all CRFs completed to the greatest extent possible. 
10.0 
DATA HANDLING AND RECORD KEEPING 
10.1 
Study Monitoring 
The investigator will allow representatives of Lycera (or their designee) to periodically monitor 
all CRFs, source documents, ICDs, and clinical laboratory records for each subject.  The purpose 
of the monitoring visits will be to: 
 Evaluate the progress of the study 
 Verify the accuracy and completeness of the CRFs 
 Verify the signed ICD, the Regulatory binder, and IP storage and records 
 Resolve any inconsistencies in the study records 
 Ensure that all protocol requirements are being fulfilled  
 Ensure GCPs are being followed 
The study site may be subject to review by the IRB/IEC, and/or to quality assurance audits 
performed by Lycera (or designee), and/or to inspection by appropriate Regulatory Authorities.   
It is important that the investigator(s) and their relevant personnel are available during the 
monitoring visits and possible audits or inspections and that sufficient time is devoted to the 
process.  
10.2 
Study Documentation 
CRFs are required and should be completed for all subjects signing informed consent.  Subjects 
who screen fail will have demographic and disposition CRF with the reason for screen fail (if 
they screen fail due to an adverse event, the AE CRF will also be collected).  For this trial, the 
CRFs are an electronic data record.  The completed original CRFs are the sole property of 
Lycera and should not be made available in any form to third parties, except for authorized 
representatives of Lycera or appropriate regulatory authorities, without written permission from 
Lycera. 

 
Clinical Protocol 
LYC-30937-2002 
Amendment 2, 22 November 2016 
 
Confidential and Proprietary 
Page 49 of 56 
It is ultimately the investigator’s responsibility to ensure completion and to review and approve 
all CRFs. Individual CRFs may be signed by the investigator or by an authorized staff member 
(and may be an electronic signature).  A final CRF must be signed by the investigator to attest 
that the information contained on the CRF is true.  At all times, the investigator has final 
personal responsibility for the accuracy and authenticity of all clinical and laboratory data 
entered on the CRFs. Subject source documents are the investigator’s subject records maintained 
at the study site.  In most cases, the source documents will be the hospital’s or the investigator’s 
chart.  In cases where the source documents are the hospital or the investigator’s chart, the 
information collected on the CRFs must match those charts. 
The CRF for questionnaires may serve as the source document.  
10.3 
Record Retention  
FDA/ICH regulations require all investigators participating in clinical drug studies to maintain 
detailed clinical data for one of the following periods: 
FDA/ICH 
 A period of at least 2 years following the date on which a marketing application (eg, 
biological license application) is approved by the FDA; 
 A period of 2 years after Lycera notifies the investigator that no further application is to be 
filed with the FDA. 
ICH 
 Subject identification codes must be retained for at least 15 years following the completion or 
discontinuation of the study. 
To enable evaluations and/or audits from regulatory authorities or Lycera, the investigator agrees 
to keep records, including the identity of all participating subjects (sufficient information to link 
records, eg, CRFs and hospital records), all original signed ICDs, copies of all CRFs, SAE 
forms, source documents, and detailed records of treatment disposition (at the end of the study).  
The records should be retained by the investigator according to ICH, local regulations, or as 
specified in the Clinical Study Agreement, whichever is longer. 
If the investigator relocates, retires, or for any reason withdraws from the study, Lycera should 
be prospectively notified.  The study records must be transferred to an acceptable designee, such 
as another investigator, another institution, or to Lycera.  The investigator must obtain Lycera’s 

 
Clinical Protocol 
LYC-30937-2002 
Amendment 2, 22 November 2016 
 
Confidential and Proprietary 
Page 50 of 56 
written permission before disposing of any records, even if retention requirements have been 
met.   
11.0 
CONFIDENTIALITY AND PUBLICATION PLAN 
11.1 
Confidentiality 
Subject’s medical information obtained as a result of this study is considered confidential, and 
disclosure to third parties other than those noted below is prohibited.  All reports and 
communications relating to subjects in this study will identify subjects only by subject number.  
Medical information resulting from a subject’s participation in this study may be given to the 
subject’s personal physician or to the appropriate medical personnel responsible for the subject’s 
welfare.  Data generated in this study are to be available for inspection on request by the FDA or 
other government regulatory agency inspectors, and the IRB/IEC but should otherwise remain 
confidential. 
11.2 
Publication of Data and Protection of Intellectual Property 
Any information about the study drug and company operations at Lycera is confidential, and 
shall remain the sole property of Lycera.  The investigator agrees to use this information only in 
conducting this study, and to not use it for other purposes without prior written consent from 
Lycera. 
The information developed in this clinical study will be used by Lycera in the clinical 
development of its compound and therefore, may be disclosed by Lycera, as required, to other 
clinical investigators, pharmaceutical companies, the FDA, and other government agencies. 

 
Clinical Protocol 
LYC-30937-2002 
Amendment 2, 22 November 2016 
 
Confidential and Proprietary 
Page 51 of 56 
12.0 
REFERENCES 
1. 
Peyrin-Biroulet L and Lemann M. Review article: Remission Rates Achievable by 
Current Therapies for Inflammatory Bowel Disease.  Aliment Pharmacol Ther (2011) 
V.33, p.870-879 
2. 
Feagen BG, Rutgeerts P, Sands BE et al. Vedolizumab as Induction and Maintenance 
Therapy for Ulcerative Colitis.  New England Journal of Medicine (2013) 
369(8):p.699-710 
3. 
Viget N, Vernier-Massouille G, Salmon-Ceron D, Yazdanpanah Y and Colombel JF.  
Opportunistic Infections in Patients with Inflammatory Bowel Disease: Prevention and 
Diagnosis.  Gut (2008) 57(4): p.549-58. 
4. 
Rungoe C, Langholz E, Andersson M et al. Changes in Medical Treatment and Surgery 
Rates in Inflammatory Bowel Disease: a Nationwide Cohort Study.  Gut (2014) 63(10): 
p.1607-16. 
5. 
Fox CJ, Hammer man PS, Thompson CB. Fuel Feeds Function: Energy Metabolism and 
the T-Cell Response. Nature Rev Immunology (2005) 5: p.844-852. 
6. 
Frauwirth KA, Thompson CB. Regulation of T Lymphocyte Metabolism. J Immunology 
(2004) 172: p. 4661-4665. 
7. 
Nelson D and Cox M, Lehninger Principles of Biochemistry, 6th ed, (2012) 
8. 
Berg J, Tymoczko J and Stryker L, Biochemistry, 7th ed, (2010) 
9. 
Bednarski J, Warner R, Rao T, Leonetti F, et al. Attenuation of Autoimmune disease in 
Fas-Deficient Mice by Treatment with Cytotoxic Benzodiazepine. Arthritis and Rheum 
(2003) 48(3):p.757-766 
10. 
Gatza E, Wahl D, Opipari A, Sundberg T, Reddy P, Lui C, Glick G, Ferrara J. 
Manipulating the Bioenergetics of Alloreactive T Cells causes Their Selective Apoptosis 
and Arrests Graft-Versus-Host Disease. Science Translational Medicine 3 (67), 67ra8  
11. 
Bhagavathula N, Nerusu K, Hanosh A, Aslam M, Opipari A, Johnson K, Kang S, Glick 
G, Varani J. Bz-423, a Benzodiazepine, suppresses Keratinocyte Proliferation and has 
Anti-Psoriatic Activity in Human Skin-SCID Mouse Transplant Model. J Pharmacol Exp 
Ther (2008) 324:p.938-947 

 
Clinical Protocol 
LYC-30937-2002 
Amendment 2, 22 November 2016 
 
Confidential and Proprietary 
Page 52 of 56 
12. 
Franchi L, Monteleone I, Morgan R, Opipari A, Carter L, Click G, Monteleone G. 
Modulation of the F1F0-ATPase Induces Apoptosis of Mouse and Human Lamina 
Propria T Cells and is Efficacious in Models of IBD. Gastroenterology (2014) 146(5): 
s112, Abstract 593 
 

 
Clinical Protocol 
LYC-30937-2002 
Amendment 2, 22 November 2016 
 
Confidential and Proprietary 
Page 53 of 56 
13.0 
APPENDICES 
13.1 
Appendix A: Total of Blood Volume 
The table below displays the approximate number and approximate volume of blood that will be 
collected per subject throughout the study.  
Total Blood Volume by Assessment 
Assessment 
Maximum # 
Samples 
mL of Blood per 
Sample 
Total Volume of 
Blood (mL) 
Lab to Analyze 
Safety 
 
 
 
 
Hematology 
8 
3 
24* 
Central Lab 
Chemistry 
8 
4 
32* 
Central Lab 
Coagulation 
2 
3 
6 
Central Lab 
 
 
 
 
 
TOTAL 
 
 
62* 
 
* 
Subjects who start the OLE study more than 3 weeks after completing double-blind Visit 7/Week 10 will have 
additional hematology and chemistry assessments performed and therefore will have an additional 
approximately 7 mL of blood collected giving an approximate total of 69 mL for the OLE study.  

 
Clinical Protocol 
LYC-30937-2002 
Amendment 2, 22 November 2016 
 
Confidential and Proprietary 
Page 54 of 56 
14.0 
DOCUMENT HISTORY 
Document 
Version Date 
Summary of Changes 
Description of Change 
Rationale 
Original Protocol 
09 May 2016 
N/A 
N/A 
Amendment 1 
23 August 2016 
 
Section 2.3.3: information consolidated;  
 
Section 2.3.3: Text revised for conciseness. IB 
contains additional detail; 
 
 
 
Section 2.4: added Phase 1b study data and 
consolidated information; 
 
Section 2.4: Text consolidated for conciseness. IB 
contains additional detail. Phase 1b preliminary 
information added for completeness; 
 
 
 
Section 4.4.1: Inclusion criteria 4 revised to require 
that women of child bearing potential use two highly 
effective forms of contraception; 
 
Section 4.4.1: Inclusion criteria 4 revised to align with 
FDA guidance related to women of childbearing 
potential using two highly effective forms of 
contraception; 
 
 
 
Section 6.2: added activity for site to telephone 
subjects to remind them to complete diary; 
 
Section 6.2: Telephone reminders to subjects added to 
reinforce dosing and diary compliance; 
 
 
 
Sections 6.2 and 6.3 revised to define days at which 
subjects should record stool frequency and rectal 
bleeding in their diary; 
 
Sections 6.2 and 6.3: Revised to provide detail on 
exploratory diary data collection; 
 
 
 
Section 6.3.6 revised to state that study drug will be 
withheld in subjects who exhibit any of the listed 
clinical lab elevations; 
 
Section 6.3.6: Revised for consistency based on FDA 
feedback on associated double-blind protocol; 
 
 
 
Section 7.4: AE severity assessment revised to use 
NCI CTCAE grading; 
 
Section 7.4: AE severity collection revised for 
consistency based on FDA input on associated double-
blind protocol; 
 
 
 
Section 7.5 revised to add sponsor medical monitor 
contact information and SAE reporting email and fax 
numbers; 
 
Section 7.5: revised to add detail on SAE reporting 
and to added sponsor medical monitor contact 
information added for completeness; 

 
Clinical Protocol 
LYC-30937-2002 
Amendment 2, 22 November 2016 
 
Confidential and Proprietary 
Page 55 of 56 
Document 
Version Date 
Summary of Changes 
Description of Change 
Rationale 
 
 
 
Section 7.11 revised to add individual stopping criteria 
based on abnormal ECG findings of prolonged 
QT/QTc interval; 
 
Section 7.11: Revised to be consistent with FDA 
request on associated double-blind protocol; 
 
 
 
Section 11.1 revised to remove statement that subjects 
will be identified by their initials. Subject initials are 
not being collected and therefore won’t be used for 
subject identification. 
 
Section 11.1: Revised to be consistent with associated 
double-blind protocol. 
Amendment 2 
22 November 2016  
Sections 1.0, 2.1, 2.2, 2.4 updated to include 
information on the Phase 1 study in patients with UC 
who received LYC-30937-EC at single doses of 25 mg 
and 100 mg;  
 
Sections 1.0, 2.1, 2.2, 2.4 updated because the 
referenced Phase 1 study information was newly 
obtained and relevant to include in this protocol 
amendment.   
 
 
 
Sections 1.0, 3.1.2, 3.2.2, 4.1, 4.5, 5.2, 6.1 – 6.2.4, 7.6, 
and 8.4 revised due to extension of the OLE treatment 
period up to 44 weeks, including the addition of study 
visits at Weeks 8, 20, 32, 44, and 46;  
 
 
Section 1.0 revised to add participating countries 
 
The primary purpose of this Amendment 2 is to extend 
the OLE treatment period up to 44 weeks; 
Sections 1.0, 3.1.2, 3.2.2, 4.1, 4.5, 5.2, 6.1 – 6.2.4, 7.6, 
7.11, and 8.4 were revised in accordance with this 
treatment extension; 
 
Added for completeness; 
 
 
 
Section 1.0 revised to include the approximate last 
subject last visit timing date; 
 
Section 1.0 updated with approximate last subject last 
visit to provide estimated end of study timing;   
 
 
 
Section 2.3.3 updated to include chronic toxicology 
information from rat and monkey studies; 
 
Section 2.3.3 updated with chronic toxicology, which 
supports extension of OLE treatment period up to 
44 weeks; 
 
 
 
Section 4.4.1 Inclusion Criteria #2 revised to clarify 
that highly effective forms of contraception include 
hormonal contraceptives which include the following 
forms: oral, patch, long acting injectable and implants; 
 
Section 4.4.1 Inclusion Criteria #2 was revised to 
clarify that the various forms of hormonal 
contraception are considered effective forms of 
contraception in this trial; 

 
Clinical Protocol 
LYC-30937-2002 
Amendment 2, 22 November 2016 
 
Confidential and Proprietary 
Page 56 of 56 
Document 
Version Date 
Summary of Changes 
Description of Change 
Rationale 
 
 
 
Section 4.5 revised to clarify that subjects who 
withdraw should complete Visits 8 and 9; 
 
Section 5.3.3 revised to clarify that drug receipt is be 
acknowledged in IWRS upon receipt of drug; 
 
Sections 6.2 (Table 1 footnote), 6.2.1, 6.4.5 updated to 
include body temperature log ; 
 
 
Section 6.4.6 direction added to understand underlying 
baseline UC symptoms of abdominal pain and 
vomiting; 
 
Revised for clarity; 
 
Revised for completeness; 
 
A body temperature log is being included to allow 
subjects to document their temperatures taken at home 
during the first week of OLE treatment; 
 
Added for clarification to ensure  baseline assessment 
of underlying  UC symptoms;  
 
 
 
Appendix A: revised the approximate blood volume 
collected. 
 
Appendix A was updated with the approximate 
volume of blood collected at the additional study visits 
necessary for the extended treatment period.